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ABSTRACT 
 
Introduction. Huntingtin gene (HTT) encodes for a high molecular weight protein (HTT) that is 
essential during gastrulation and in forebrain formation. The N-terminal region of the protein has 
been recently associated to in vitro pro-neurulation activity. This region includes a peculiar CAG 
repeat stretch whose expansion results in an inherited neurodegenerative disorder named 
Huntington’s disease (HD). The disease itself, its penetrance and age of onset are dependent on the 
length of CAG stretch that encodes for a polyglutamine (polyQ) tract. Evolutionary studies showed 
that this polyQ tract appeared for the first time in echinoderms, then increased in length during 
deuterostome evolution in parallel to the emergence of progressively more complex nervous systems. 
Despite these indications, the functional significance of the polyQ variability in normal HTT remains 
to be explored. 
Aim. Here we investigate whether the polyQ tract in HTT is biologically active during early 
neurogenesis. In particular, as a tool to study in vitro neurogenesis, we adopted the rosette assay, an 
in vitro assay that measures the ability of ES cell-derived neural progenitors to form radial 
arrangements of columnar cells (named neural rosettes) that mimic neural tube formation in vivo. 
Additionally, we worked on designing a novel automated method for faster and unbiased 
quantifications of the rosette phenotype. 
Methods. We produced a mouse embryonic stem (mES) cell-based platform for complementation 
assays with HTT N-terminal portion bearing different polyQ repeats, their deletion and substitutions 
(0Q, 2Q, 4Q, 7Q, 15Q, 128Q, Q3Q(CAA)Q3, and Q3PQ3). The newly generated cells were exposed 
to a neural induction protocol to assess their rosette formation potential. 
Results. We report that the pro-neurulation activity, but not the antiapoptotic function, of HTT is 
impaired by the sole polyQ domain deletion from the N-terminal portion of HTT. Moreover, the 
CAG tract length affects rosette formation potential in a linear fashion. Conversely, either a 
pathological CAG expansion or a CAG interruption causes loss of HTT N-terminal pro-neurulation 
activity. Finally, to further characterize this phenotype in an unbiased and quantitative way, we 
developed and tested a novel automated system, based on high-content imaging approach that 
allowed us to pinpoint this trait with unparalleled precision and efficiency. 
Conclusions. Overall, these results demonstrate that HTT ability to promote rosette formation is 
linked to a persistent and uninterrupted CAG tract, while HTT antiapoptotic activity lays outside 
HTT polyQ domain. 
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Huntingtin (HTT) is a high molecular weight protein (348kDa) that is encoded by the Huntingtin gene (HTT); 
also known as IT-15 and maps on chromosome 4. While the human HTT protein (NCBI RefSeq: NP_002102) 
is 3144 amino acids long, the mouse protein (NP_034544) contains 3120 amino acids. When excluding the 
differences in their polyglutamine (polyQ) tract and proline-rich domain (PRD), the human and mouse proteins 
are 91% identical and 95% similar (Ehrnhoefer et al., 2009). 
An expansion of the CAG repeats (CAGs) within the coding region of the HTT results in an elongated stretch 
of glutamine (Q) in the HTT N-terminus that causes an inherited autosomal dominant neurodegenerative 
disorder named Huntington’s disease, HD (HD Collaborative Research Group, 1993). In the non-HD 
population the CAG triplet is repeated between 9 and 35 times, while an expansion above 36 repeats results in 
the development of the disease. Rare carriers of 36 to 39 CAGs show a lower penetrance and later onset of the 
disease compared to those with 40 or more CAGs (McNeil et al., 1997; Quarrell et al., 2007). The 
neuropathology of HD results in a massive brain neurodegeneration characterized by the prevalent dysfunction 
and loss of specific neurons (efferent medium spiny neurons) in the striatum of the basal ganglia, which is the 
principal responsible for the typical HD symptoms (Reiner et al., 1988). However, corticostriatal projection 
neurons are also particularly affected and a more widespread degeneration of the brain (including the layers V 
and VI of cortex) is also reported (Rosas et al., 2003, 2005, 2008). HD symptoms include generalized motor 
dysfunction, psychiatric decline and cognitive disturbances. Although alterations of the central nervous system 
(CNS) are the main characteristics of the disease, patients also show alterations at the metabolic level, such as 
immune disturbances, osteoporosis, cardiac failure, weight loss and testicular and skeletal muscle atrophy (van 
der Burg et al., 2009). The symptoms last about 20 years after onset, and death often occurs for fatal aspiration 
pneumonia. Today there is still no cure for HD. 
As HD develops because of the dominant toxic activity of a single mutant allele, the majority of the studies in 
the field are focussed on investigating the impact of mutant HTT on neuronal and brain function. However, the 
study of the biology of normal HTT and its function allows a better understanding on how exactly the mutant 
protein causes the disease and can give new perspectives on future therapeutic targets. Therefore, the 
laboratory in which this thesis has been performed, together with others, has focused on identifying HTT 
native functions and its physiological roles. Based on these studies published over the past 20 years, in the first 
section of this thesis work I describe the literature regarding the evolution, structure and known functions of 
the wild-type HTT gene. 
 
 
1.1 HTT structure and function 
1.1.1 HTT gene evolution 
The HTT gene can be traced back very early in life history, before the divergence between protostomes and 
deuterostomes (occurred approximately 670 mya according to Erwin et al., 2011). Indeed, an ortholog of the 
HTT gene, that carries no CAGs, is found in the very ancient organism Dictyostelium discoideum (Palidwor et 
al., 2009; Myre et al., 2011; Figure 1.1). Dictyostelium D. is a soil-living amoeba that lives mostly as a single-
celled separate organism, but during starvation they are able to stream together to form a multicellular 
organism. Although the inactivation of HTT gene in Dictyostelium does not compromise cell growth, it leads to 
the loss of capacity to form a multicellular organism (Myre et al., 2011). It has been also shown that the 
Dictyostelium HTT gene inactivation impairs cytokinesis, cell shape, chemotaxis, and homophilic cell-cell 
adhesion during hypo-osmotic stress (Myre et al., 2011; Wang et al., 2011). Our laboratory has shown that 
Dictyostelium HTT is antiapoptotic when the corresponding gene is expressed in mammalian cells (Lo Sardo et 
al., 2012). This function is related to the N-terminal portion of HTT and is conserved in mammals (Rigamonti 
et al., 2000, 2001; Zuccato et al., 2010).  
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Most of the studies regarding HTT function in protostomes come from Drosophila melanogaster, whose 
HTT gene has 29 exons. Drosophila HTT protein was predicted to be composed of 3583 amino acids and, in 
contrast to mammals, lacks the polyQ and proline-rich domain (PRD) (Li et al., 1999). HTT in Drosophila is 
ubiquitously expressed during all stages of fly development (Li et al., 1999). Although there is no polyQ tract 
in the N-terminal portion of Drosophila HTT (Figure 1.1), several polyQ stretches are found in other portions 
of the protein (e.g., Drosophila yakuba has 10 and 12 glutamines at position 625 to 634 and 1118 to 1131, 
respectively) which are lacking in the human HTT, suggesting that in Drosophilae lineages independent polyQ 
tract insertion events have occurred (Schaefer et al., 2012). Moreover, bioinformatic analyses of HTT from 
Drosophila melanogaster, Drosophila pseudoobscura, Apis mellifera (honey bee), and Tribolium castaneum 
(red flour beetle) revealed a more heterogeneous evolution in insect class compared with deuterostomes 
(Tartari et al., 2008). Putative HTT null mutant of Drosophila shows normal gastrulation (unlike mice), 
suggesting that in Drosophila the protein is not involved in embryogenesis (Zhang et al., 2009; Zuccato et al., 
2010). These two different phenotypes reveal apparent differences in the mouse/fly embryonic developmental 
process (Li et al., 1999; Tartari et al., 2008) or may be the result of compensatory mechanisms for the loss of 
the protein in the HTT knock-out flies (Zheng and Joinnides, 2009). Further studies in adult HTT knock-out 
Drosophila did not show any defect in synapse formation, neurotransmission, or axonal transport even if a 
decreased number of branches of giant fiber neurons were observed (Zhang et al., 2009). In contrast, 
Gunawardena and his group reported the involvement of Drosophila HTT in axonal transport and 
synaptogenesis (Gunawardena et al., 2003). Loss of HTT also revealed mobility defects and reduced viability 
in aged flies, suggesting an important role of the protein in adulthood (Zhang et al., 2009).  
 
More recent findings revealed that specific functions of HTT are conserved between flies and mammals. 
An in vitro experiment found that Drosophila HTT may functionally replace the missing murine HTT protein, 
validating the conservation of the protein’s function (Godin et al., 2010). By using an in vitro assay, our 
laboratory has shown that Drosophila HTT has an antiapoptotic role and that this activity is also well 
conserved in the deuterostome lineage (Lo Sardo et al., 2012). Indeed, this function appeared in Dictyostelium 
and has then been maintained during evolution, as showed by the ability of heterologous HTT proteins (from 
sea urchin, Ciona, anphioxus, zebrafish, mouse, and human) to promote cell survival (Lo Sardo et al., 2012). 
The axonal transport function of HTT is also conserved across mammals and flies (Zala et al., 2013). 
 
In order to discover relevant huntingtin domains and activities, a series of HTT homologues from both 
protostome and deuterostome branches have been cloned and used to construct a first multiple alignment in the 
N-terminal region of HTT. In particular, the protein sequence of organisms that represent fundamental turning 
points in the phylogenetic tree, with regards to the development and evolution of the nervous system, have 
been reconstructed. The sequence of HTT from echinoderm Strongylocentrotus purpuratus (purple sea urchin) 
(Tartari et al., 2008), urochordate Ciona intestinalis (tunicate sea squirt) (Gissi et al., 2006), and 
cephalocordate Branchiostoma floridae (amphioxus) (Candiani et al., 2007), together with HTT from insects 
and vertebrates have been used to identify the putative HTT domains and to evaluate the evolutionary 
relevance of the polyQ tract. 
The first appearance of the polyQ tract in HTT is in the Strongylocentrotus purpuratus that carries an 
NHQQ sequence in the N-terminal portion. This portion can be considered biologically comparable to the four 
glutamines found in lower vertebrates (Tartari et al., 2008; Figure 1.1 and 1.2). Two glutamines are also 
present in the cephalocordate Branchiostoma floridae (Candiani et al., 2007), but here they are preceded by 
two hydrophobic amino acids (alanine and phenylalanine, AF) in contrast with the two polar amino acids 
(asparagine and histidine, NH) present in the sea urchin. Another difference exists between the N-terminal 
sequences of the two organisms, which is the presence of a 21 residues tract upstream of the NHQQ of the sea 
urchin; this tract appears different in composition with respect to the amphioxus. All these findings suggest a 
putative stabilization of the polyQ tract in the N-terminal portion of the amphioxus HTT due to selective 
evolutionary pressure (Candiani et al., 2007; Tartari et al., 2008). Surprisingly, HTTs of the tunicates Ciona 
savigny and Ciona intestinalis have no polyQ tract, and they have probably suffered a deletion in the N-
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terminal portion which is shorter than in their vertebrate orthologs (Gissi et al., 2006). Although Ciona 
possesses the main chordate traits during neural development, these differences in protein sequence are not 
unexpected because these urochordates quickly diverged from the other chordates, probably due to adaptation 
of their specific ecologic niche (Hughes and Friedman, 2005). 
 
In vertebrates the length of the polyQ tract increases, from 4 to 35 glutamines (threshold for the healthy 
human population) (Figure 1.1 and 1.2). In particular, 4 glutamines are present in fish, amphibians, reptiles 
and birds. Six glutamines are found in HTT from the marsupial Monodelphis domestica (gray short-tailed 
opossum), 7 in Mus musculus (mouse), 8 in Rattus norvegicus (rat), 10 in Canis familiaris (dog), 15 in Bos 
taurus (domestic cow), and 18 in Sus scrofa (pig) (Figure 1.1 and 1.2). Moreover, the analyses of the polyQ 
tract in non-human primates from 10 different species revealed that the number of glutamines was remarkably 
consistent between species, ranging from 7 to 16Q (Rubinsztein et al., 1994). The sequencing findings of our 
unpublished work are in line with this polyQ length range in non-human primates (Figure 1.1 and 1.2). In 
humans, the polyQ tract reaches the longest and most polymorphic length, from 9 to 35.  
 
Early studies suggested that the normal human CAG repeats are not in equilibrium but instead appear to be 
subject to a mutational bias that causes a gradual expansion of the CAG length (Rubinsztein et al., 1994). A 
full discussion of the CAG repeats in humans and their biological meaning is given in chapter 1.2. As 
mentioned before, a PRD domain follows the polyQ tract. However, this domain appears exclusively in higher 
vertebrates and specifically in mammals and thus represents a recent and sudden acquisition of a particular 
region in the evolution of HTT (Figure 1.2). Although many authors propose that this region is able to 
stabilize the polyQ tract by keeping it soluble (Steffan et al., 2004), an open question remains about the 
function of the PRD.    
 
 
 
 
 
Figure 1.1. HTT polyQ tract evolution along the human lineage. Schematic illustration of a phylogenetic tree of 
huntingtin polyQ tract from amoeba Dictyostelium discoideum to humans. Number of Q repeats within the polyQ tract is 
reported. 
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Figure 1.2. Representative multiple sequence alignment of HTT N-terminus in 55 sequences along the human 
lineage. The polyQ and PRD portions are highlighted in violet and green, respectively. In the N-17 region (yellow) and in 
the C-terminal region (blue) only amino acids differing from consensus are highlighted according to the colour scheme of 
Lesk algorithm (reported in the bottom).  
 
1.1.2 HTT expression and distribution  
Analysis of HTT expression revealed that both in humans and mice the protein is ubiquitously distributed, even 
if the highest levels have been detected in CNS and testis (Strong et al., 1993; Landwehrmeyer et al., 1995; 
Sharp et al., 1995; Bhide et al., 1996; Sapp et al., 1997; Vonsattel and DiFiglia, 1998).  
HTT gene in human and rodents has two mRNA isoforms (Htt). These transcripts (10366 bp and 13711 bp) 
are generated by alternative cleavage and polyadenylation of the primary transcript; the second transcript, in 
particular, differs by an additional 3’ UTR sequence of 3360 bp (Lin et al., 1993, 1994). While the long 
transcript is predominantly expressed in the brain of both species, the shorter transcript seems to be more 
widely expressed. Later studies also reported that mutant HTT gene is also mis-spliced, generating a short 
polyadenylated mRNA. This transcript is translated into a pathogenic exon 1 HTT protein (Sathasivam et al., 
2013). Only very recently, a study reported an alternative splicing for HTT originating protein variants that 
lack exons 10, 12, 29, and 46 or, alternatively, retain a 57 bp portion of intron 28 or even an additional exon 
(41b) (Hughes et al., 2014; Ruzo et al., 2015). These HTT isoforms are rare, however some of them could be 
upregulated during development. Moreover, the absence of these exons may lead to changes in HTT 
susceptibility to cleavage, phosphorylation, and ability to interact with other proteins (Hughes et al., 2014; 
Ruzo et al., 2015). 
 
HTT is expressed from post-fertilization stages, as revealed by an expression study in mouse and human 
development (Dragatsis et al., 1998). Later, HTT expression increases in concomitance with the neuronal 
maturation in the post-natal stage (Bhide et al., 1996). Furthermore, evolutionary analyses highlighted that 
HTT is predominantly present in non-neural tissues in the sea urchin (Heliocidaris herithrogramma), while it 
is ubiquitously distributed in the primitive chordate sea pineapple (Halocynthia roretzi) with highest 
expression level in the nervous system (Kauffman et al., 2003). Likewise, in amphioxus (Branchiostoma 
floridae) an increased HTT expression level has been shown in the nervous system, with the strongest level 
being present in the most anterior part of neural tube (Candiani et al., 2007). On the whole, these results 
suggest that the neural expression of HTT could be a chordate-specific feature. 
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Within the nervous system, HTT expression is not restricted to the brain regions that degenerate in the HD, 
indeed HTT is also found in other brain areas. In particular, when analysing mouse and human post-mortem 
brain, HTT expression was especially abundant in neurons of the telencephalon and thalamus, but had a poor 
expression in the hypothalamus (Strong et al., 1993; Landwehrmeyer et al., 1995; Sharp et al., 1995; Bhide et 
al., 1996; Sapp et al., 1997; Vonsattel and DiFiglia, 1998). In the telencephalon, HTT-positive neurons are 
found in the neocortex, especially the pyramidal neurons of layers 3 and 5, which project to the striatum (Fusco 
et al., 1999). Also the hippocampus exhibited high level of HTT expression, particularly the pyramidal neurons 
of the CA2 and CA3 layers. The same study revealed that the striatum contains scattered large neurons rich in 
HTT and more numerous medium-sized neurons with a moderate HTT content (Fusco et al., 1999). The CAG-
expansion mutation of the HTT gene seems to have no effect on the regional expression of HTT in the brain 
(Aronin et al., 1995; Landwehrmeyer et al., 1995; Schilling et al., 1995; Bhide et al., 1996; Sapp et al., 1997; 
Vonsattel and DiFiglia, 1998).  
 
Regarding intracellular localization, HTT is present in the soluble cytoplasmic compartment, as well as in 
cell bodies, dendrites, and axons (Sharp et al., 1995; Vonsattel and DiFiglia, 1998). Further studies identified 
HTT in brain membrane fractions (Suopanki et al., 2006), suggesting an interaction between HTT and lipids. 
Moreover, HTT interacts with vesicle membrane and microtubules (DiFiglia et al., 1995; Gutekunst et al., 
1995; Sharp et al., 1995), where it plays a role in axonal and vesicular transport. HTT is also located to the 
endoplasmic reticulum (ER) as a consequence of an activity embedded into the first 18 amino acids of HTT N-
terminus (Atwal and Truant, 2008). This domain is also capable of targeting HTT to late endosomes as well as 
in autophagic vesicles, implying a putative role of HTT in vesicles trafficking and in the formation of 
autophagic vacuoles (Atwal and Truant, 2008). In addition, HTT localizes to the Golgi complex and 
perinuclear tubulovesicular membranes (Velier et al., 1998; Strehlow et al., 2007) and is associated with 
mitochondria (Gutekunst et al., 1998; Hilditch-Maguire et al., 2000; Panov et al., 2002; Choo et al., 2004). 
Finally, nuclear localization has been described for wild-type HTT (Hoogeveen et al., 1993; De Rooij et al., 
1996; Sapp et al., 1997; Dorsman et al., 1999; Wilkinson et al., 1999; Kegel et al., 2002). A dynamic 
movement of HTT across the nuclear membrane has also been reported. This capacity is associated to the 
HEAT repeats (Truant et al., 2006) and regulated by a nuclear import signal located in the HTT N-terminus 
(Atwal et al., 2007; Desmond et al., 2012) and by a nuclear export signal located in the HTT C-terminus (Xia 
et al., 2003). Finally, HTT localizes at the mitotic spindle pole (Godin et al., 2010), where it regulates cell 
division; this localization seems to be associated to the HTT phosphorylation at serines 13 and 16 (Godin et al., 
2010; Atwal et al., 2011; Maiuri et al., 2013). 
 
1.1.3 HTT structure 
The high molecular weight of HTT protein hampers the use of classical approaches (production of crystals and 
mass spectrometry studies) for elucidating its structure; therefore, most of the structural findings derive from 
computational analyses. Most of the HTT studies were focused on the N-terminal region of the protein and 
specifically on the HTT exon 1 (encoding for amino acids 1 to 68, as it contains the expandable polyQ tract). In 
addition to this tract, exon 1 contains a portion encoding for the first 17 amino acids of HTT (named N17) that 
precedes the polyQ tract, and a PRD domain that follows the polyQ tract. Both polyQ tract and PRD are 
polymorphic in humans.  
 
The N17 portion is highly conserved in vertebrates but less in protostomes (Tartari et al., 2008). This 
region acts as a nuclear export signal (NES) and its structure is an amphipathic α-helix (Atwal et al., 2007), 
which is significant for retention in the endoplasmic reticulum (Atwal et al., 2007; Rockabrand et al., 2007). 
Many post-translational modifications (PTMs) are present in the N17, such as acetylation, sumoylation, and 
ubiquitination at lysines 6, 9, and 15 (K6, K9 and K15) and phosphorylation at serines 13 and 16 (S13 and S16, 
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respectively) that affect the clearance of HTT and its subcellular localization (Table 1.1) (Atwal et al., 2007; 
Maiuri et al., 2013; Steffan et al., 2004; Thompson et al., 2009).  
 
The first three-dimensional structure of a polyQ stretch was revealed by Max Perutz and his team in 1994. 
They showed that a peptide of 15 Qs was able to adopt a β-sheet structure and that a combination of these units 
can form the “polar zipper” atomic model, which consists of antiparallel β-strands held together by hydrogen 
bonds (Perutz et al., 1994). They also suggested that the physiological function of the polyQ tract was to bind 
transcription factors that contain another polyQ region (Perutz et al., 1994). The PRD, typical of the 
mammalian group, is variable and is important for the interaction with proteins that contain tryptophans or Src 
homology 3 domains (Schaefer et al., 2012). It has a proline-proline (PP) helix, a rigid structure that adopts 
kinked or straight conformation (Kim et al., 2009). The PP helix of the PRD functions as stabilizer of the 
polyQ tract, to avoid a conformational collapse, and this ability may account for a known role played by PRD 
region in the aggregation/toxicity of mutant HTT (Bhattacharyya et al., 2006; Darnell et al., 2007; Dehay and 
Bertolotti, 2006; Duennwald et al., 2006; Kim et al., 2009). Notwithstanding the above mentioned 
characteristics, the deletion of the PRD domain in vivo has no pronounced effect on mouse behavior 
(Neveklovska et al., 2012). X-ray crystallography resolved the secondary structure of an HTT N-terminal 
region carrying 17Q. In particular, while the N17 portion forms an α-helical structure, the poly17Q stretch 
adopts multiple flexible conformations including α-helix, random coil, and extended loop (Kim et al., 2009). 
The conformation of the poly17Q region is influenced by the conformation of neighbouring domains, 
demonstrating the importance of the native protein context (Kim et al., 2009). 
The putative roles of these three HTT domains (polyQ, PRD and N17) have been investigated in vivo. In 
particular, the consequence of deleting mouse HTT N17, polyQ and PRD domains, or a combination of them, 
in vivo, support the idea that these domains are dispensable for HTT critical functions during early embryonic 
development, but are likely more important for HTT functions in later CNS development or maintenance 
(Clabough and Zeitlin, 2006; Zheng et al., 2010; Neveklovska et al., 2012; André et al., 2017). 
 
The rest of the protein (66 exons encoding amino acids from 69 to 3144) is less well characterized. A 
secondary structure analysis of full-length HTT showed that it is composed of about 40% α-helix, 12%, β-
strand and 48% turn and coil (Huang et al., 2015). Further studies showed the presence of several HEAT 
repeats, so called because they are found in Huntingtin, Elongation factor 3, protein phosphatase 2A, and the 
yeast kinase TOR1. The HEAT repeats are amino acid sequences (about 40aa long) that occur multiple times 
within a protein, and they are formed of antiparallel α-helices separated by a non-helical portion. These 
repeated regions are important for protein-protein interaction (Andrade and Bork, 1995; Neuwald and Hirano, 
2000; Andrade et al., 2001; Palidwor et al., 2009). The HEAT repeats of HTT are well conserved in 
deuterostomes, suggesting that they are an ancestral feature in HTT evolution. In particular, bioinformatics 
analyses reported between 16 and 36 HEAT repeats clustered into three to five three-dimensional structures, 
called α-rod domains, separated by disordered regions (Figure 1.3) (Palidwor et al., 2009; Takano and 
Gusella, 2002; Tartari et al., 2008; Warby et al., 2008). The HEAT repeat domains may function as a 
solenoid-like structure that acts as a scaffold for numerous protein complexes and mediates inter- and intra-
molecular interactions. The middle region of HTT (507-1230aa) can bind to the N-terminal (1-506aa) and C-
terminal (2721-3144aa) domains of HTT (Palidwor et al., 2009); the 507-1230aa domain can also self-
associate to form HTT homodimers. Other studies demonstrated that two HTT N-terminal portions (1-416aa 
and 1-586aa) bind to different C-terminal regions of HTT (1725-2800aa and 2416-3144aa, respectively), and 
these intramolecular interactions are disrupted upon proteolysis (El‐Daher et al., 2015; Ochaba et al., 2014). 
Very recently a study on the full-length HTT revealed that it is composed of five distinct domains and 
confirmed that HTT adopts a spherical α-helical solenoid structure where the N-terminal and C-terminal 
regions fold to contain a circumscribed central cavity. Interestingly, the authors also showed that the polyQ 
tract expansion increases the α-helical properties of HTT and affects the intramolecular interactions among the 
domains (Vijayvargia et al., 2016). All these observations suggest that HTT can adopt various three-
dimensional conformations, depending on its intra-molecular interactions. These interactions may also involve 
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other proteins to form complexes, and in support of this, numerous HTT interactors have been found (see 
paragraph 1.1.4). Consistently, purified HTT can adopt up to 100 structurally distinguishable conformations 
(Seong et al., 2010). 
Finally, other functional motifs able to regulate HTT function or localization have been identified (Xia et 
al., 2003), such as the NES site at position 2397-2406aa. 
 
1.1.4 HTT PTMs, proteolysis, and interactors 
HTT post-translational modifications (PTMs). HTT undergoes multiple PTMs, including phosphorylation, 
acetylation, palmitoylation, ubiquitination, and sumoylation (Figure 1.3; Table 1.1). The role of these PTMs has 
been analysed mostly in the context of the mutant polyQ protein. HTT PTMs are critical for HTT stability, 
cellular localization, modulation of protein-protein interactions, regulation of vesicle transport and autophagy. 
Moreover, these modifications could also impact on the function of other proteins (Zuccato et al., 2010; Saudou 
and Humbert, 2016). Several PTMs have a therapeutic relevance, as they modulate toxicity of mutant HTT, and 
result in phenotypic changes in animal models of HD (Graham et al., 2006; Gu et al., 2009). Most of the 
reported PTMs in HTT are localized in the four PEST domains, so called because they are amino acid sequences 
enriched in proline (P), glutamate (E), serine (S), and threonine (T) (Warby et al., 2008). For a complete list of 
HTT residues subjected to PTMs see Table 1.1.  
 
HTT proteolysis. Huntingtin protein is subjected to proteolysis at several sites by a variety of proteases some of 
which are unknown. The proteolytic sites are in PEST domains that are mostly found in HTT disordered regions 
(Figure 1.3) (Warby et al., 2008). The first reported proteases able to cleave HTT are the caspases (Goldberg et 
al., 1996; Wellington et al., 1998; Hermel et al., 2004), followed by the calpains (Gafni and Ellerby, 2002; Kim 
et al., 2001, 2003; Gafni et al., 2004), cathepsins, in particular aspartyl proteases (Lunkes et al., 2002; Kim et al., 
2006) and MMP10, a metalloproteinase (Miller et al., 2010).  
HTT proteolysis is relevant in the protein stability and homeostasis. Furthermore, caspases activity has 
been associated to synaptic plasticity, memory, and learning (Li et al., 2010), it is therefore possible that 
proteolytic cleavages of HTT protein could be involved in the regulation of these processes. A recent study 
showed that the proteolysis of wild-type HTT may inactivate some of its functions through the production of 
toxic non-polyQ C-terminal fragments (El‐Daher et al., 2015). Nevertheless, no proteolytic events of wild-
type HTT were reported in normal individuals. On the contrary, in HD brains a specific increase of the 
proteolytic activity was described with a consequent accumulation of small N-terminal HTT fragments. 
Importantly, the toxicity of these fragments is due to their translocation into the nucleus (Benn et al., 2005; 
Graham et al., 2006; Saudou et al., 1998). It has also been proposed that PTMs and proteolysis work in a 
cooperative manner to modulate several protein functions (Tan et al., 2010).  
 
HTT interactors. Many studies aimed at discovering putative partners of HTT (Harjes and Wanker, 2003; 
Goehler et al., 2004; Kaltenbach et al., 2007; Ratovitski et al., 2012; Culver et al., 2012). These studies led to 
more than 350 wild-type HTT potential partners. In a few cases, the functional relationship between wild-type 
HTT and its interacting proteins has been established. For instance, HTT interacts with PSD95 (Sun et al., 2001), 
with Huntingtin-Associated Protein 1 (HAP1) and the p150 subunit of dynactin (Gauthier et al., 2004), with 
Mixed-Lineage Kinase 2 (MLK2) (Marcora et al., 2003), and with Huntingtin-Interacting Protein 1 (HIP1) 
(Gervais et al., 2002). Another relevant example is that wild-type HTT can promote the expression of BDNF by 
interacting through REST-interacting LIM domain protein (RILP) and HAP1 with the repressor element-1 
transcription factor/neuron-restrictive silencer factor (REST/NRSF) in the cytoplasm; in this way, this complex 
does not translocate into the nucleus and is prevented from binding to the repressor element 1/neuron-restrictive 
silencer element (RE1/NRSE) located in the promoter of the BDNF gene and other neuronal genes (Shimojo, 
2008; Zuccato et al., 2003). HTT large size and its stability, together with the high number of partners identified, 
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argue in favour of HTT being a scaffold protein. For example, HTT scaffolds Dynein/Dynactin to regulate 
several cellular processes such as vesicular transport, cell division and ciliogenesis (Figure 1.4) (Saudou and 
Humbert, 2016). Noteworthy, it has been shown that few proteins interact with the internal or the C-terminal part 
of HTT. This finding is in line with intramolecular interactions observed between the N-terminal and C-terminal 
regions (El‐Daher et al., 2015; Li et al., 2006; Ochaba et al., 2014; Palidwor et al., 2009). Indeed, as a result 
of these interactions, HTT can adopt a closed conformation and allow only a few limited interactions between 
the C-terminal region and other proteins.  
 
 
 
 
 
 
 
 
Figure 1.3. Cartoon of the human HTT protein sequence (from Saudou and Humbert, 2016). Amino acid (aa) positions 
in orange: phosphorylation sites identified by mass spectrometry and further confirmed by other approaches. Amino acid 
positions in black: sites of indicated modifications. Amino acid positions in blue: cleavage sites. Cp1, cleavage site by 
unknown protease; Cp2/BLMH/CTZ, cleavage by Bleomycin hydrolase or cathepsin Z; Casp6? is a confirmed cleavage 
site: while initially identified as a caspase 6 site, caspase 6 may not be the cleaving protease in vivo. Orange and black stars 
indicate, respectively, phosphorylation and acetylation sites identified by mass spectrometry only with no further 
confirmations. Numbers arranged linearly on the 2D structure correspond to the limits of the indicated domains (HEAT, 
PEST, and Highly disordered regions). H indicates the number of predicted HEAT repeats organized in larger domains and 
PEST regions are proteolysis-sensitive domains. Highly disordered regions correspond to predicted disordered regions 
using PONDR, DisEMBL, and NORSp. Bottom: Schematic HTT with spheres that correspond to stretches of HEAT 
repeats. HTT could adopt multiple conformations according to Seong et al., 2010. Ubi, ubiquitin; Sumo, sumoyl; Acet, 
acetyl; Palm, palmitoyl; MMP10, metalloproteinase 10; Calp, calpain; Casp3/2/6, caspase 3/2/6. 
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Residue	 Modification	 Enzyme	 Function	 Analysis	 References	
Thr	3	 Phos	 	 	 MS/Ab	 Aiken	et	al.	(2009),	Huang	et	al.	(2015)	
Lys	6	 Ubi/Sumo	 	 	 IV	 Steffan	et	al.	(2004)	
Lys	9	 Acet/Ubi/Sumo	 	 	 MS/IV	 Cong	et	al.	(2011),	Steffan	et	al.	(2004)	
Ser	13	 Phos	 IKK	 K9/Ubi/Sumo	 MS/Ab	 Thompson	et	al.	(2009)	
Lys	15	 Ubi/Sumo	 	 	 IV	 Steffan	et	al.	(2004)	
Ser	16	 Phos	 IKK	 K9/Ubi/Sumo	 MS/Ab	 Thompson	et	al.	(2009)	
Ser	116	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	120	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Lys	178	 Acet	 	 	 MS	 Cong	et	al.	(2011)	
Cys	214	 Palm	 	 	 MS/IV-Palm	 Yanai	et	al.	(2006)	
Lys	236	 Acet	 	 	 MS/Ab	 Cong	et	al.	(2011)	
Thr	271	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Lys	345	 Acet	 	 	 MS/Ab	 Cong	et	al.	(2011)	
Ser	417	 Phos	 Akt/PKA?	 	 MS	 Huang	et	al.	(2015),	Watkin	et	al.	(2014)	
Ser	419	 Phos	 Akt/PKA?	 	 MS	 Huang	et	al.	(2015),	Moritz	et	al.	(2010)	
Ser	421	 Phos	 Akt/SGK1/PP2B	 Axonal	transport	 MS/Ab	 Huang	et	al.	(2015),	Humbert	et	al.	(2002),	Moritz	et	al.	(2010),	Pardo	et	al.	(2006),	Rangone	et	al.	(2004),	Schilling	et	al.	(2006),	Watkin	et	al.	(2014)	
Ser	431	 Phos	 	 	 MS/Ab	 Dong	et	al.	(2012),	Huang	et	al.	(2015),	Watkin	et	al.	(2014)	
Ser	432	 Phos	 	 	 MS/Ab	 Dong	et	al.	(2012),	Huang	et	al.	(2015)	
Ser	434	 Phos	 Cdk5	 Casp-3	site	513	 Ab/MS	 Huang	et	al.	(2015),	Luo	et	al.	(2005),	Watkin	et	al.	(2014)	
Ser	438	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Lys	444	 Acet/Ubi	 CBP/HDAC1	 autophagy	 MS/Ab	 Cong	et	al.	(2011),	Jeong	et	al.	(2009)	
Ser	457	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	459	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	461	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	464	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	465	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	466	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	487	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Thr	488	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	491	 Phos	 	 	 MS	 Watkin	et	al.	(2014)	
Ser	536	 Phos	 PKC?	 Calp	536	site	 MS	 Schilling	et	al.	(2006)	
Ser	642	 Phos	 Akt?	 	 MS	 Huang	et	al.	(2015),	Moritz	et	al.	(2010)	
Ser	644	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	645	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	1181	 Phos	 Cdk5	 axonal	transport	 MS/Ab	 Anne	et	al.	(2007),	Huang	et	al.	(2015),	Schilling	et	al.	(2006)	
Ser	1197	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	1201	 Phos	 Cdk5	 axonal	transport	 MS/Ab	 Anne	et	al.	(2007),	Huang	et	al.	(2015),	Schilling	et	al,	(2006)	
Ser	1351	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Tyr	1357	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	1866	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	1868	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Thr	1872	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	1876	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	2076	 Phos	 ERK1?	 	 MS	 Schilling	et	al.	(2006)	
Thr	2337	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	2550	 Phos	 	 	 MS	 Huang	et	al.	(2015)	
Ser	2653	 Phos	 ERK1?	 	 MS	 Huang	et	al.	(2015),	Schilling	et	al.	(2006)	
Ser	2657	 Phos	 GSK3?	 	 MS	 Huang	et	al.	(2015),	Schilling	et	al.	(2006)	
 
 
Table 1.1. HTT Post-translational Modifications (adapted from Saudou and Humbert, 2016). The identification of the 
modifications was performed using mass spectrometry (MS), specific antibodies against the modified sites (Ab), and 
in vitro assays (IV; IV-Palm: in vitro palmitate assay) as indicated. Thr, threonine; Lys, lysine; Ser, serine; Cys, cysteine; 
Tyr, tyrosine; Phos, phosphorylation; Ubi, ubiquitination; Sumo, sumoylation; Acet, acetylation; Palm, palmitoylation. 
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1.1.4 HTT functions 
The numerous physiological outputs of wild-type HTT functions are relevant both in the developing and in 
mature organism; these outputs at an integrated level (tissue or whole organism) may correspond to a limited 
set of functions at the molecular level. A current question in the field is whether the neurodegeneration 
observed in the adult HD brain may a consequence of developmental defects.  
Here, we will address HTT functions at an integrated level by analysing its role in embryonic development, 
tissue maintenance and cell morphology, and cell survival. Some HTT functions have also been elucidated at 
the molecular level, such as the involvement of HTT in vesicular transport, cell division, ciliogenesis, 
endocytosis, vesicle recycling, and endosomal trafficking, autophagy, gene transcription regulation, and 
synaptic activity (Saudou and Humbert, 2016; Liu and Zeitlin, 2017). 
HTT in development 
Huntingtin was shown to be essential for embryonic development, since the inactivation of HTT gene is lethal 
in mice. In particular, HTT is critical for gastrulation (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 
1995) and for CNS formation (White et al., 1997; Auerbach et al., 2001). Although the studies of the HTT 
functions in vivo during gastrulation are hindered by the early lethality of knock-out embryos, a role for HTT 
in neurogenesis is emerged, and severe alterations of the brain development were shown (White et al., 1997).  
 
Gastrulation. The constitutive inactivation of the HTT gene by targeting exon 1 or 5 is lethal in mice between 
embryonic day 8.5 and 10.5; this stage is shortly after the onset of gastrulation and the formation of early 
nervous system (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995). This seems to be a direct 
consequence of an increased apoptosis in the embryonic ectoderm. Moreover, it has been shown that chimeric 
embryos derived by the injection of HTT null embryonic stem (ES) cells into wild-type host blastocysts are 
rescued from lethality (Dragatsis et al., 1998). In contrast, when wild-type ES cells are injected into HTT null 
blastocysts, the chimeric embryos die shortly after gastrulation, demonstrating that HTT acts in the extra-
embryonic tissues, whereas the epiblast and its derivatives are affected secondarily (Dragatsis et al., 1998). 
More specifically, an altered nutritive function of the extra-embryonic tissues in the absence of HTT has been 
discovered (Dragatsis et al., 1998). In line with this observation, extra-embryonic tissues lacking HTT reveal 
defects in iron transport (Dragatsis et al., 1998). Coherent with this idea, HTT knock-down analyses in zebrafish 
model showed a deficiency in iron utilization and development (Lumsden et al., 2007). 
 
Neural tube formation. HTT was found to be critical in the formation of nervous system. The first evidence 
came from an experiment in which mice expressing less than 50% wild-type HTT showed defects in the 
precursor of the epiblast, the structure that will give rise to the neural tube, and malformations of the cortex and 
striatum. Additionally, these mice died shortly after birth (White et al., 1997; Auerbach et al., 2001). In a further 
experiment it was shown that the reduction of HTT levels in zebrafish generates defects in the formation of most 
of the anterior regions of the neural plate, in the telencephalic progenitor cells and in the preplacodal tissue 
(Henshall et al., 2009). This shows the HTT is involved in neural tube formation at the post-gastrulation stage. 
Evidence that HTT is involved in neurulation comes from experiments with HTT null mouse embryonic stem 
(mES) cells as well as HTT knock-down zebrafish embryo. In particular, wild-type ES cells subjected to neural 
differentiation protocol give rise to 3D structures named neuroepithelial rosettes (Ying et al., 2003a). These 
neural structures emerge at days 7-8 of the neural differentiation protocol and are known to recapitulate many 
aspects of neural tube development and early stages of the neurulation process (Elkabetz et al., 2008; 
Abranches et al., 2009). HTT-depleted mES cells are less capable to form neuroepithelial rosettes (Lo Sardo et 
al., 2012). Further investigations showed that the N-terminal fragment of HTT, but not its C-terminal portion, 
completely rescued neurulation in complementation assays performed in HTT-depleted ES cells (Tartari et al., 
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2008; Lo Sardo et al., 2012). In addition to in vitro studies, experiments in zebrafish support the idea that HTT 
is implicated in neurulation. Indeed, embryos injected with Htt-morpholino showed an altered neural tube 
structure and defects in cellular adhesion and apicobasal polarity (Lo Sardo et al., 2012). 
The pro-neurulation function of HTT is specific of the deuterostome group. In fact, complementation 
assays using HTT-depleted ES cells expressing heterologous HTT fragments showed that the ability to sustain 
neurulation was almost absent in Dictyostelium and Drosophila, subtle in sea urchin and Ciona (lower 
deuterostomes), whereas it was more evident with HTT fragments from the cephalochordate Branchiostoma 
floridae and even stronger with HTT from fish and mammals (Lo Sardo et al., 2012). Given that the 
amphioxus represents a critical step in the transition from invertebrates to vertebrates and in the acquisition of 
a more complex nervous system (Holland et al., 2004), the presence of pro-neurulation activity by HTT in this 
organism suggests a crucial role of this protein in the evolutionary dawn of the nervous system in chordates. 
The appearance of the HTT polyQ tract in echinoderms, and its subsequent stabilization in chordates, points in 
the direction of a putative implication of this tract in driving the transition toward vertebrate nervous system 
complexity. 
One of the more characterized pathways by which HTT regulates neurulation includes two proteins 
implicated in the cell adhesion mechanism (Lo Sardo et al., 2012). The first protein is N-cadherin that is 
specifically required for the morphology of neural tube (Detrick et al., 1990; Fujimori et al., 1990; Radice et 
al., 1997; Lele et al., 2002; Hong and Brewster, 2006; Chalasani and Brewster, 2011); the second one is the 
metalloprotease ADAM10, an activator of N-cadherin protein (Reiss et al., 2005). In addition, it has been 
shown that synapse-associated protein 97 (SAP97) is responsible for driving ADAM10 to the postsynaptic 
membrane (Marcello et al., 2007). A recent work demonstrated that HTT binds ADAM10, and this interaction 
prevents the formation of ADAM10/SAP97 complex, regulating N-cadherin cleavage during neurulation (Lo 
Sardo et al., 2012). The absence of HTT increases the formation of ADAM10/SAP97 complex and causes an 
altered cleavage of N-cadherin, leading to neurulation defects as showed by the reduced ability to form in vitro 
neuroepithelial rosettes of the HTT-depleted mES cells, previously mentioned. It has been also found that in 
zebrafish embryos the morphological neural tube defects due to HTT loss-of-function is rescued by the 
pharmacological inhibition of ADAM10 (Lo Sardo et al., 2012). Another indication that validates the 
involvement of N-cadherin in the neurulation pathway comes from experiments where N-cadherin zebrafish 
mutants show neurulation defects (Lele et al., 2002). In particular, by analysing the expression patterns of the 
floor plate together with markers of apicobasal polarity, it has been shown that HTT knock-down in zebrafish 
embryos phenocopies N-cadherin zebrafish mutants (Lo Sardo et al., 2012). This finding confirms that HTT 
controls neuroepithelial cell adhesion and morphogenesis of the neural tube by influencing ADAM10/N-
cadherin functionality.  
Overall these results support the idea that HTT may regulate critical steps during the nervous system 
formation, particularly in neurulation, and that this function may have had an impact on the evolution of 
deuterostomes. 
 
Cortical neurogenesis. HTT plays a role also during the later phases of brain development, in particular the 
protein is relevant for cortical neurogenesis. In vivo inactivation of huntingtin by RNA interference or by 
ablation of the HTT gene affects spindle orientation and cell fate of cortical progenitors of the ventricular zone in 
mouse embryos (Godin et al., 2010). More specifically, HTT was found on the spindle pole and, by recruiting 
dynein/dynactin complex and other molecular complexes (such as the NUclear Mitotic Apparatus, NUMA), it 
controls mitotic spindle orientation (Godin et al., 2010). This function is also present in Drosophila, indeed the 
specific disruption of Drosophila HTT in neuroblast precursors leads to spindle misorientation; suggesting that 
this function is conserved during evolution. Moreover, Drosophila HTT restores spindle misorientation in 
mammalian cells (Godin et al., 2010). 
 
Cortical neuroblast migration. Another role of HTT regards the migration of cortical neuroblasts from the 
ventricular zone to the cortical plate (Tong et al., 2011). It was reported that the knock-down of HTT expression 
in neuroepithelial cells of neocortex results in disturbed cell migration, reduced proliferation, and increased cell 
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death. In the cerebellum, however, HTT knock-down results in cell death but not in perturbed migration. The 
timing of knock-down during early development is also an important variable. Based on these results, a spatial 
and temporal requirement for HTT expression in neural development is evident (Tong et al., 2011). Finally, the 
phenotypic abnormalities of impaired migration and cell death were only found in transfected cells while 
neighboring non-transfected cells showed no defects, implicating a non-cell autonomous mechanism (Tong et 
al., 2011).  
 
Neural identity. Studies of mutant mice expressing low levels of HTT and analyses in chimeric mice generated 
by blastocyst injection of HTT null ES cells confirm that wild-type HTT plays an important role later in 
development as well, specifically in forebrain formation.  
Early studies reported a specific role of HTT for the development of cortical and striatal neurons; in particular, 
HTT appears to be required for proliferation or survival of neurons in some brain regions during early 
development. Indeed, HTT-depleted cells preferentially colonize hypothalamus, midbrain, and hindbrain and 
are scarce in cortex, striatum, thalamus, and Purkinje cell layer of the cerebellum suggesting that neurons in 
these regions may strictly require HTT to develop and/or survive normal (Reiner et al., 2001). Further analyses 
of chimeric embryos at E12.5 showed ongoing degeneration of HTT-depleted cells specifically in the striatum, 
cortex, and thalamus, corroborating the view that neuroblasts in these areas need to synthesize HTT if they are 
to progress in development and differentiation (Reiner et al., 2001, 2003). Finally, it has been discovered that 
neurons, throughout the brain, require HTT for long-term survival (Reiner et al., 2001). These results are in 
line with the data collected using conditional HTT knock-out mice, in which the loss of HTT late in 
development or shortly after birth impacts the survival of cortical and striatal neurons in the adult brain 
(Dragatsis et al., 2000). Another mechanism by which HTT impacts on brain development is the regulation of 
motile cilium biogenesis (Keryer et al., 2011). In particular, conditional inactivation of the HTT gene in Wnt1 
cell lineages results in congenital hydrocephalus, implicating HTT in the regulation of cerebral spinal fluid 
(CSF) homeostasis (Dietrich et al., 2009; Keryer et al., 2011). 
HTT regulates tissue maintenance and cell morphology 
In parallel to the role of HTT during brain development, recent studies implicate HTT is a regulator of tissue 
maintenance. Indeed, depletion of HTT, in vivo, results in a decreased pool and specification of basal and 
luminal progenitors in the mammary epithelium. This leads to altered mammary morphogenesis probably due 
to mitotic spindle misorientation (Elias et al., 2014). HTT is also relevant for the establishment of apical 
polarity and, consequently, the depletion of HTT from luminal cells in vivo alters mouse ductal morphogenesis 
together with impaired lumen formation (Elias et al., 2015). 
Further evidences of HTT roles in the regulation of epithelial morphogenesis have been found. In 
particular, the previous described involvement of HTT in the cell adhesion mechanism, as showed by aberrant 
distribution of the tight junction protein zona occludens 1 (ZO1) in HTT null ES cells and Htt morpholino 
zebrafish embryos, is one example (Lo Sardo et al., 2012). Moreover, ES cells and neurons with lowered HTT 
levels have shown reduced amounts of mRNAs of adherence proteins (Strehlow et al., 2007). Consistent with 
these observations, mice with reduced HTT expression in testis show spermatogenesis defects that result in 
disorganized seminiferous tubules with fewer spermatocytes and round spermatids (Dragatsis et al., 2000). 
Another recent evidence reports that HTT is involved in the maintenance of tight junctions, in particular it has 
been shown that reduced amounts of HTT causes a greater epithelial-to-mesenchymal transition in mammary 
tumour cells (Thion et al., 2015). 
Finally, HTT may also impact on histogenesis and organogenesis by regulating metabolism. In vivo 
experiments showed that mice overexpressing wild-type HTT have an increased body weight as well as 
enlarged heart, spleen, liver, kidneys, and lungs. These findings are the result of a HTT dose-dependent 
modulation of the insulin-like growth factor 1 (IGF-1) expression (Pouladi et al., 2010; Van Raamsdonk et al., 
2006). 
Introduction 
 
 
20 
HTT in cell survival 
Several in vitro and in vivo studies highlighted the pro-survival (antiapoptotic) properties of wild-type HTT. A 
first set of experiments showed that expression of wild-type HTT in cell lines and primary cultures of neurons 
protects against cell death. In particular, striatal cells overexpressing wild-type HTT were resistant to serum 
deprivation or exposure to 3-nitropropionic acid (a toxin that gives a similar pattern of HD neurodegeneration 
when injected into animals) (Rigamonti et al., 2000, 2001). Further analyses discovered that this antiapototic 
activity is embedded in the HTT N-terminus, since both full-length normal HTT and its 548 amino acid N-
terminus were able to protect cells against cell death (Rigamonti et al., 2000). Interestingly, normal HTT is 
protective also when the cell death is induced by mutant HTT itself; indeed, it was shown that wild-type HTT 
can protect non-neuronal cell lines (Ho et al., 2001) and primary striatal neurons (Leavitt et al., 2006) from 
apoptosis resulting from mutant HTT. Conversely, depletion of HTT renders cells more vulnerable to cell 
death in line with an increased level of caspase-3 activity (Zhang et al., 2006; Lo Sardo et al., 2012). The 
antiapoptotic function of HTT seems to be conserved during evolution as the expression of heterologous HTT, 
including HTT from Drosophila melanogaster and Dictyostelium discoideum, in HTT-null mES cells exhibited 
anti-apoptotic activity. 
These in vitro observations were supported by in vivo studies in mouse. Earlier analysis in a heterozygous 
HTT knock-out mouse model revealed apoptotic cell death in several areas, cognitive dysfunction, and 
behavioural abnormalities (Nasir et al., 1995; O’Kusky et al., 1999). Moreover, neuronal-specific inactivation 
of the HTT gene in the postnatal forebrain generated apoptotic cells in the hippocampus, cortex, and striatum, 
as well as a lack of axon fibers (Dragatsis et al., 2000). Analysis of a mouse model in which HTT is 
selectively deleted from adult mature cortical and hippocampal neurons demonstrated defects in both the 
survival and the dendritic arborization of newborn hippocampal neurons (Pla et al., 2013). These findings 
associate endogenous wild-type HTT with adult hippocampal neurogenesis. Furthermore, the controlled 
deletion of wild-type HTT had anxiogenic-like effects, suggesting that some of the mood disorders (very 
common among HD patients) may be caused by an alteration of normal HTT function in the hippocampus and 
cortex (Pla et al., 2013). Apoptotic cell death was also found in Htt-morpholino knock-down zebrafish 
embryos, in which an increased caspase-3 activity and a severe underdevelopment of the CNS were observed 
(Diekmann et al., 2009). More recently, a non-coding SNP (Single Nucleotide Polymorphism) variant in the 
HTT promoter was found (Bečanović et al., 2015). This genetic variant on the wild-type HTT allele reduces its 
expression, and is associated with earlier age of onset in HD patients (Bečanović et al., 2015), supporting the 
idea that HTT levels can impact cell survival.  
The antiapoptotic/pro-survival activities of HTT are very pertinent to HD. Indeed, one of the most 
prominent histopathological features of post-mortem HD brain samples is the severe neuronal atrophy of 
several brain regions; this massive atrophy may cause a reduction of up to 30% in brain weight (Rosas et al., 
2008). The cell death associated with the presence of mutant HTT is recapitulated in cellular and mouse 
models (Gray et al., 2008; Saudou et al., 1998). 
The first attempts to decipher the molecular details of how normal HTT promotes survival focused on the 
apoptotic machinery. Wild-type HTT prevents the formation of a functional apoptosome complex and, 
consequently, blocks the activation of caspase-3 (Rigamonti et al., 2000) and caspase-9 (Rigamonti et al., 
2001). HTT can also interact with active caspase-3 and inhibit its activity (Zhang et al., 2006). In addition, 
HTT blocks the formation of caspase-activating complex HIPPI, hampering pro-caspase-8 activation (Hackam 
et al., 2000; Gervais et al., 2002). A further analysis indicated that HTT is a substrate for Akt, a 
serine/threonine-specific protein kinase that activates a pro-survival pathway by stimulating the expression of 
pro-survival genes and repressing pro-apoptotic genes (Rangone et al., 2004). Another mechanism by which 
HTT promotes cell survival is exemplified by the nature of the cortico-striatal connection. The striatum does 
not produce BDNF and depends almost exclusively on the BDNF delivered by cortico-striatal afferences 
(Baquet et al., 2004). In this context, HTT favours the transcription of BDNF (Zuccato et al., 2001) and 
promotes the axonal transport and delivery of vesicles containing BDNF to the cortico-striatal synapse 
(Gauthier et al., 2004). When BDNF is released at cortico-striatal synapses, it promotes endocytosis and the 
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retrograde transport of TrkB receptors (Tropomyosin receptor kinase B) to striatal cell bodies where they 
activate survival signalling (Liot et al., 2013). TrkB binds to and colocalizes with HTT and dynein. It has been 
shown that silencing HTT reduces vesicular transport of TrkB in striatal neurons and, additionally, that HTT 
polyQ expansion in HD alters the binding of TrkB-containing vesicles to microtubules and reduces axonal 
transport (Liot et al., 2013). HTT, thus, ensures both the anterograde delivery of BDNF to the cortico-striatal 
synapse and also the retrograde transport of BDNF-TrkB endosomes along striatal dendrites towards the cell 
bodies. Therefore, given the central role of HTT in these processes and, consequently, in the survival of striatal 
neurons, it is not surprising that these neurons are the first to degenerate in HD.  
 
 
 
 
 
 
Figure 1.4. Huntingtin scaffolds Dynein/Dynactin to regulate several cellular processes (from Saudou and Humbert, 
2016). Top: HTT controls the transport of organelles, in both anterograde and retrograde directions, and in axons and 
dendrites within neurons. Middle: During mitosis, HTT is important for spindle pole assembly and also regulates the 
kinesin1-dependent trafficking of dynein/dynactin/NUMA/LGN to the cell cortex. Bottom: HTT mediates the 
dynein/dynactin/HAP1-dependent transport of proteins to the pericentriolar material, including PCM1 protein that is 
required for ciliogenesis. MT, microtubules; PCM, pericentriolar material. 
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1.2 CAG trinucleotide repeats 
1.2.1 Simple sequence repeats and their biological meaning 
The HTT CAG repeats are one example of a broader group of tandem repeats, also called simple sequence 
repeats (SSRs), present in the human genome. These SSRs have been first described in the early ‘80s and are 
present in many eukaryotic genomes (from yeast to humans) (Hamada et al., 1982). In addition, many human 
genes possess multiple SSRs. These repeats have a propensity for “slippage mutations”, which increase or 
decrease the number of repeats without altering the content of the sequence (Richards and Sutherland, 1994). 
The abundant polymorphism, which results from repeated slippage events, has become the basis for DNA 
fingerprinting, lineage analysis and gene mapping. This mutability, together with the apparent lack of 
information contained in such repetitive “genetic stutters”, appeared once to preclude any possibility of critical 
function for the SSRs. Indeed, much of the literature on SSR polymorphism has assumed (Ellegren, 2004) that 
SSRs are genetic ‘junk,’ supplying only ‘neutral’ variation with no appreciable effect on phenotype. On the 
contrary, since Hamada and colleagues first established that altering the number of repeated dinucleotides 
could affect gene activity (Hamada et al., 1982) and according to their genome localization (gene promoters, 
introns, and exons), many examples of repeat-number-related effects came to light.  
 
Interestingly, at least 20 different neurological disorders (such as HD, Spinocerebellar ataxia, and Myotonic 
dystrophy) are caused by expanded SSRs (reviewed in Nithianantharajah and Hannan, 2007; Orr and Zoghbi, 
2007). Such diseases are frequently characterized by “genetic anticipation”, an hereditary tendency toward 
further expansion of pathological repeat alleles in each generation, leading to earlier onset and accelerated 
disease progression in subsequent generations. In addition to their effects at pathological level, SSR alleles can 
also contribute to normal variation in brain and behavioural traits (Fondon et al., 2008). Indeed, many studies 
implicate SSRs not just in diseases but also in circadian rhythmicity, socio-sexual interaction, aggression, 
cognition and personality. SSRs have been suggested also to affect neuronal differentiation, brain development 
and even behavioural evolution (Fondon et al., 2008). In particular, SSR polymorphism contributes to normal 
quantitative genetic variation in traits ranging from cell adhesion in yeast to skeletal morphology in dogs 
(Kashi et al., 1997; Kashi and King, 2006; Fondon et al., 2008). Three best-studied examples of the 
relationships among SSR polymorphism, phenotype and molecular function involve three genes influencing 
animal behaviour: PER gene in Drosophila melanogaster, AVPR1A gene in Microtus sp. (field mice) and 
SLC6A4 gene in primates.  
 
First, Drosophila PER protein contains a tract of threonine-glycine and serine-glycine dipeptide repeats 
encoded by a hexanucleotidic SSR in exon 5. It has been shown that flies with 20 repeats resulted in reduced 
sensitivity of circadian rhythm to temperature fluctuations compared to those with a shorter 17 repeats (Sawyer 
et al., 1997). Moreover, in Europe, northern Africa and Australia 20-repeat alleles were more frequent in flies 
sampled at higher latitudes, suggesting that natural selection discriminates among alleles of different lengths 
based on their ability to compensate the temperature in regions exposed to greater temperature fluctuations 
(Kyriacou et al., 2008). Interspecies comparisons, including gene transplantation experiments, also support a 
functional role of the PER SSRs; in particular, these studies revealed a coevolutionary compensation between 
the effect of SSRs and flanking sequence variants (Peixoto et al., 1998). 
Secondly, several converging lines of evidence identify functional SSR variation in the 5’- regulatory 
region of the AVPR1A (Arginine Vasopressin Receptor 1A) gene in Microtus ochrogaster (prairie voles) as a 
significant contributor to social behaviour such as selective partner preference and offspring care (Hammock 
and Young, 2005). In particular, comparison between prairie voles whose parents carried longer than average 
SSR alleles and those whose parents had shorter alleles revealed differences in V1aR (Vasopressin receptor 
1A) protein distribution in the brain as well as alterations in vasopressin-dependent social behaviour 
(Hammock and Young, 2005). Additionally, mice that are transgenic for the prairie vole variant of the gene 
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have a neuroanatomical pattern of receptor binding that is similar to that of the prairie vole, and exhibit 
increased affiliative behaviour after injection with arginine vasopressin. These data indicate that the pattern of 
AVPR1A gene expression in the brain may be functionally associated with species-specific social behaviours in 
mammals (Young et al., 1999). Indeed, whereas SSR length correlates with brain and behavioural traits among 
individual prairie voles, phylogenetic analysis of other vole species has established that SSR in AVPR1A gene 
is not by itself a reliable marker for complex social behaviour which depends on multiple brain circuits, 
environmental context and many genes (Hammock and Young, 2005; Fink et al., 2006). 
Thirdly, one of the best examples in humans involves a polymorphic SSR (designated 5-HTTLPR) located 
in the upstream promoter region of the serotonin transporter gene, SLC6A4. A classical study showed that the 
shorter of two common alleles, which yields lower levels of gene expression in transcription reporter assays, 
was correlated with increased neuroticism, tension and harm avoidance (Lesch et al., 1996). However, many 
subsequent studies have failed to corroborate those associations or have otherwise presented conflicting 
findings (Sen et al., 2004; Munafò et al., 2005). Additionally, individuals carrying two long alleles of this SSR 
appear to be somewhat protected from the negative effects of significant life stress (Caspi et al., 2003). 
Notably, gene-environment interactions are an important consideration in human association studies and can be 
used to clarify conflicting findings. Furthermore, a similar (but not identical) polymorphism (rh5-HTTLPR) 
was discovered in the rhesus macaque (Macaca mulatta) serotonin transporter gene. Like in humans, the 
shorter of these polymorphism alleles has a lower gene expression in vitro and was associated with reduced 
levels of the serotonin metabolite 5-HIAA (Bennett et al., 2002), increased distress during assessment 
(Champoux et al., 2002), and greater inhibition by anxiety-provoking novel environments (Bethea et al., 2004). 
Curiously, early dispersal of male offspring from their natal group has also been associated with the shorter 
allele (Trefilov et al., 2000). For a more complete list of candidate-gene sites where SSR polymorphisms were 
associated with human behaviour see Table 1.2. 
 
Another feature of the SSR repeats is the somatic mosaicism found in several neurodegenerative repeat-
expansion diseases (Telenius et al., 1994; Ueno et al., 1995; Tanaka et al., 1996; Gonitel et al., 2008). 
However, numerous observations suggest the presence of SSR somatic variations also during normal brain 
development where they can exert a direct impact on gene function (Hamada et al., 1984; Trifonov, 1989; 
Gerber et al., 1994; Kashi et al., 1997; King et al., 1997; Comings, 1998; King and Soller, 1999; Fondon and 
Garner, 2004; Kashi and King, 2006). In spinocerebellar ataxia 2 (SCA2), it is not the length of the inherited 
allele per se but the susceptibility of the SSRs to hyperexpansion, and the subsequent somatic variation, which 
are responsible of the pathogenicity. This pathogenicity can be reduced by the stabilizing influence of repeat 
interruptions as shown by the discovery of individuals who possessed expanded alleles but who never 
developed the symptoms of this otherwise fully penetrant disease. Closer investigations revealed the presence 
of silent slippage-suppressing CAA interruptions within the CAG repeat sequence (Choudhry et al., 2001). 
Additional examples of the stabilization of otherwise pathological repeat alleles by repeat interruptions have 
been reported (Sobczak and Krzyzosiak, 2004; Mulvihill et al., 2005; Matsuura et al., 2006). Interestingly, it 
was also found that the presence of interruptions in SCA10 repeat expansion indicates a significant risk for the 
epilepsy phenotype (McFarland et al., 2014), suggesting that, in some instances, repeat interruptions can 
contribute to additional phenotypes beyond the typical disease repertoire. As mentioned above, the mitotic 
slippage could also produce somatic variation in normal conditions. Non-pathological somatic SSR mutations 
occur, indeed, during several processes of organogenesis. For example, the SSR slippage mutations in the 
coding region of the melanocortin receptor gene during skin development cause black spotting in domestic red 
pigs (Kijas et al., 2001). Another example, is represented by the somatic hypermutation of antibody genes 
(Beale and Iber, 2006). Finally, the enrichment of SSRs in genes involved in neuronal differentiation and 
function (Karlin et al., 2002) raises the intriguing possibility that somatic mutation of SSRs might be a normal, 
perhaps even essential, component of brain development (Nithianantharajah and Hannan, 2007). 
Overall the characteristics of SSRs have prompted speculation that their mutability could play an important 
and potentially beneficial role in evolution (Kashi et al., 1997; King et al., 1997; King and Soller, 1999; 
Fondon and Garner, 2004; Kashi and King, 2006; King and Kashi, 2007; Kovtun and McMurray, 2008; King, 
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2012). Thus, the triplet repeat-expansion diseases represent only the pathological extreme of a much more 
general mutational process, which also contributes to normal brain function and development. 
 
Gene	 SSR	type	and	motif	 Affected	trait	 Evidence	
Serotonin	transporter	SERT	
(SLC6A4),	5-HTTLPR	
Noncoding,	5′	promoter;	44	base-pair	motif	 Anxiety-related	traits	 In	vitro	and	in	vivo	assays;	inconsistent	association	studies;	moderated	by	life	stress;	similar	results	in	rhesus	macaque	
Serotonin	transporter	SERT	
(SLC6A4)	
Noncoding,	intron;	17	base-pair	motif	 Susceptibility	to	bipolar	disorder,	response	of	SERT	to	lithium	
Association;	in	vitro	assays	
Dopamine	receptor	DRD4	 Coding;	48	base-pair	motif	 Novelty-seeking	behaviours	 Association	
Dopamine	transporter	DAT1	
(SLC6A3)	
Noncoding,	3′	UTR;	40	base-pair	motif	 Attention	deficit	hyperactivity	disorder;	episodic	memory	formation	
In	vitro	and	in	vivo	assays;	association	
DNA-binding	protein	Jarid2	 Coding;	tetranucleotide	motif	 Schizophrenia	 Association	
Androgen	receptor	 Coding;	CAG	repeat	 Cognitive	function	 Association	
α2b-adrenoceptor	ADRA2B	 Coding;	imperfect	glutamic	acid	repeat	 Emotional	memory	 Association;	in	vitro	assays	
Arginine	vasopressin	
receptor	AVPR1a	
Noncoding,	upstream;	dinucleotide	repeats	 Altruism,	other	social	behaviours	 Association;	post	mortem	gene	expression	
 
 
Table 1.2. Several aspects of human behaviour are associated with repeat-number variation (adapted from Fondon et 
al., 2008).  
 
1.2.2 HTT CAG repeats variability in human population 
The discovery of the gene responsible of HD allowed many researchers to focus on its CAG repeat tract, not 
only at the pathological level but also in normal conditions. Early epidemiological studies show that HTT CAG 
repeats in the human gene are not in equilibrium but are subjected to an ongoing process of expansion. The 
CAGs in the normal human population vary between 9 and 35 repetitions with the most common CAG size 
being 17 repeats (Kremer et al., 1994). Moreover, the degree of spread of the CAG repeats is biased toward the 
high CAG repeats (Rubinsztein et al., 1994).  
 
More recent findings indicate that pathological HTT alleles continually mutate from a pool of intermediate 
alleles (IAs), which are healthy genes with a number of repetitions between 27 and 35 (Goldberg et al., 1993; 
ACMG/ASHG HD Genetic Testing Working Group, 1998; Costa et al., 2003). IAs were first identified in 
unaffected family members, parents and siblings, of individuals with apparently de novo HD mutations. De 
novo mutations for HD result from CAG repeat instability, which expands an intermediate allele into the HD 
range (Goldberg et al., 1993; Myers et al., 1993; Almqvist et al., 2001). One out of 17 people carry this 
intermediate allele (Semaka et al., 2013). The factors currently known to influence the risk of intermediate 
allele instability include the CAG repeat size, the sex and age of the transmitting parent, the family history and 
the HD gene sequence and haplotype (Semaka et al., 2006). In particular, the finding that new mutations for 
HD arise from IAs (27-35 CAGs) and not from normal alleles (<27 CAGs) supports a role for CAG repeat size 
in repeats instability (Chong et al., 1997). Additionally, it has been shown that expanded IAs are preferentially 
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transmitted by males with advanced paternal age (mean 36.7 years) (Goldberg et al., 1993). Conversely, there 
are no documented cases of maternal intermediate allele expansion resulting in an affected offspring (Kremer 
et al., 1995). However, the fact that substantial expansions of maternally transmitted alleles with as few as 36 
repeats have occurred provides evidence that expansions of large maternal intermediate alleles into the disease 
range are theoretically possible (Laccone and Christian, 2000). Spermatogenesis has been postulated to 
account for the observed difference between male and female germline repeat expansion (Kremer et al., 1995; 
Telenius et al., 1995). During spermatogenesis, there are frequent rounds of DNA replication throughout adult 
life; on the contrary oocytes form prior to birth. It was speculated that numerous rounds of DNA replication in 
spermatogenesis increases the likelihood of CAG repeat expansion in paternal transmission, as this process 
may provide a greater opportunity for a large expansion to occur (Goldberg et al., 1993; Chong et al., 1997; 
Pearson et al., 2005). Alternatively, during spermatogenesis there may be a higher opportunity to accumulate 
numerous small expansions that incrementally increase the CAG size into the HD range (Goldberg et al., 
1993; Chong et al., 1997; Pearson et al., 2005). Furthermore, the context of family history allows to categorize 
intermediate alleles as either general population intermediate alleles (GP:IA) or new mutation intermediate 
alleles (NM:IA). GP:IAs are randomly ascertained from the general population and are coincidentally 
identified within the context of a family history of HD. Conversely, NM:IAs are ascertained from new HD 
mutation families. Familial transmission studies and examination of the CAG size heterogeneity in sperm 
analyses showed that, while IA repeat expansion into the HD range is more common in new mutation families, 
the likelihood that offspring of GP:IA carriers inherit a CAG size in the disease expanded range is extremely 
low, if not negligible (Goldberg et al., 1995; Chong et al., 1997; Kelly et al., 1999). Another important factor 
that influences the risk of intermediate allele expansion is the genetic variability near its repeat tract (cis-
elements) (Almqvist et al., 1994; Cleary et al., 2002; Cleary and Pearson, 2003, 2005; Pearson et al., 2005). 
Accordingly, detailed haplotypes using numerous single nucleotide polymorphisms (SNPs) located across the 
HTT gene were constructed (Warby et al., 2009b). In particular, these findings suggest that in Caucasians, 
CAG repeat expansion occurs primarily in two haplogroup variants (named A1 and A2 haplotypes). Thus, one 
can hypothesize that IAs found on these high-risk haplotypes might be more prone to repeat instability. The 
current data also argue, and further support, that cis-elements have a crucial predisposing influence on CAG 
instability in HTT (Warby et al., 2009b). Interestingly, a significant correlation was found between the CAG 
repeat length of the maternal and paternal allele in the HTT gene among healthy subjects, suggesting an 
assortative mating (Nopoulos et al., 2011a). It was suggested that this might be among the mechanisms at the 
origin of the evolutionary pressure toward longer CAG alleles reported in the human population.  
 
Several human studies suggest “positive effects” in subjects carrying more CAG repeats in HTT gene. One 
study conducted on 278 normal subjects revealed an increase of grey matter within the pallidum with 
increasing long CAG repeats in the normal range (Mühlau et al., 2012), concluding that CAG size influences 
normal brain structure. Secondly, pre-manifest adult HD patients having a CAG length in the pathological 
range, but that are distant from the expected age of onset, appear to perform better than control subjects in 
perceptual sensitivities tests, with a clear benefit from long CAGs in the gene (Beste et al., 2012). Thirdly, an 
unpublished study by P. Nopoulos on pre-manifest HD positive children (12 years of age) carrying up to 44 
CAG repeats show better visual and motor skills compared to normal healthy controls (oral communication, 
CHDI Therapeutic Conference 2013). Finally, HD patients carrying an increased number of repeats in the 
normal allele exhibited less severe cognitive symptoms (Aziz et al., 2009). All these studies will require further 
independent validation. In particular, one recent study has disputed the conclusion by Aziz and his group (Lee 
et al., 2012), however only motor and not cognitive deficits were analysed.  
 
Collectively, these lines of evidence are in agreement with the hypothesis that the different number of 
CAGs in the HTT gene may act as a genetic modulator of brain function and/or behaviour and correlates with 
aspects of cognitive performance in a length-dependent manner from low to borderline CAG in the normal 
range. 
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1.3 ESCs: Cell-based platform to study HTT functions 
1.3.1 Embryonic Stem Cells (ESCs) 
In this thesis work we investigated the role of the polyQ tract in HTT neural function by exploiting in vitro 
differentiation of mES cells towards a neural fate that represents a powerful and easy tool to study neurulation 
in vitro. Therefore, in this section I will illustrate the main features of mouse Embryonic Stem Cells (mESCs), 
describing the extraordinary properties of these cells in being able to give rise to differentiated derivatives of 
the three primary germ layers and highlighting also some differences with human Embryonic Stem Cells 
(hESCs). 
The three main features that identify the ESCs are: pluripotency (the capability of differentiating into 
tissues derived from all three germ layers), self-renewal (maintenance of an undifferentiated state) and 
unlimited proliferation (Smith, 2001; Niwa, 2007; Nichols and Smith, 2011). The capacity of stem cells to 
differentiate into specialized cell types and be able to give rise to any mature cell type is referred to as potency. 
Potency of the stem cell specifies the differentiation potential and, according to such potential, it is possible to 
classify: totipotent, multipotent, pluripotent, oligopotent, and unipotent cells. 
(i) Totipotent cells can differentiate into embryonic and extraembryonic cell types. Such cells can construct 
a complete, viable organism. These cells are produced from the fusion of an egg and sperm cell. The 
only totipotent cells are the fertilized egg and the cells produced by the first few divisions of the 
fertilized egg are also totipotent. Totipotent cells give rise to somatic stem/progenitor cells and primitive 
germline stem cells (Weissman, 2000).  
(ii) Pluripotent stem cells are the descendants of totipotent cells and can differentiate into all cells derived 
from any of the three germ layers, but they are not able to generate the extraembryonic trophoblast. 
These pluripotent cells are characterized by self-renewal and a differentiation potential for all cell types 
of the adult organism (Horie et al., 2011). Embryonic stem cells fall under this category, as they are 
able to generate all cell types of the body in vivo and in culture. 
(iii) Multipotent stem cells can differentiate into a limited number of cells, only those of a closely related 
family of cells. For example, the bone marrow contains adult hematopoietic stem cells, multipotent stem 
cells that give rise to all the cells of the blood but not to other types of cells. 
(iv) Oligopotent stem cells can differentiate into only a few cells, such as lymphoid or myeloid stem cells. 
The corneal epithelium is a squamous epithelium (Singh et al., 2010) that is constantly renewing and 
contains oligopotent stem cells (Majo et al., 2008). 
(v) Unipotent cells can produce only one cell type, their own, but have the property of self-renewal, which 
distinguishes them from non-stem cells. Most epithelial tissues self-renew throughout adult life due to 
the presence of unipotent progenitor cells (Blanpain et al., 2007). Spermatogonial cells are an example 
of unipotent progenitor cells, as they can only give rise to sperm cells (Jaenisch and Young, 2008). 
The first mES cells were successfully derived directly from mouse blastocysts by Evans and Kaufman from the 
University of Cambridge (Evans and Kaufman, 1981) and by Martin from the University of California, in 1981 
(Martin, 1981). Some years later, also human ES cell lines were derived (Thomson et al., 1998). The culture 
conditions for retaining pluripotency included a feeder layer of mitotically inactivated mouse fibroblasts and 
fetal calf serum that was batch-selected to promote proliferation and retain an undifferentiated phenotype. The 
initiative to derive pluripotent cell lines from early embryos was inspired by studies on teratocarcinoma cells 
(Kleinsmith and Pierce, 1964).  
Mouse ES cells are derived directly from the inner cell mass (ICM) of the blastocyst between embryonic 
day (E) 3.5 and E4.5. At E4.5, the blastocyst contains three cell types: the trophectoderm, the hypoblast and the 
epiblast. While the trophectoderm and the hypoblast contribute to extraembryonic tissues, the epiblast gives 
rise to all cell types of the developing embryo (Osorno and Chambers, 2011). This pre-implantation epiblast 
cell population contains cells that have the ability to differentiate into derivatives of all three somatic lineages 
and the germline. Generally, ES cells require extrinsic growth factors to maintain their pluripotency in culture. 
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These extrinsic growth factors act on different signalling pathways to regulate intrinsic transcription factor 
networks to sustain ES cells in the undifferentiated state. The main pathways are: LIF/JAK/STAT3, BMP 
signalling, TGF-β/activin/nodal signalling, and FGF/MEK signalling (Han et al., 2013) (Figure 1.5). 
 
Leukaemia inhibitory factor (LIF) (Hirai et al., 2011) and bone morphogenetic protein 4 (BMP4) (Qi et al., 
2004). were found to be necessary for the retention of mES cells in a pluripotent state in vitro. Upon LIF 
binding, the LIF receptor (LIFR) recruits the transmembrane glycoprotein 130 (gp130) to form a heterodimer 
which subsequently activates Janus kinase (JAK) through transphosphorylation (Niwa et al., 1998). Activated 
JAK then phosphorylates gp130, creating a docking site to bind the SH2 domain of Signal Transducers and 
Activators of Transcription 3 (STAT3) (Ihle and Kerr, 1995; Stahl et al., 1995; Hemmann et al., 1996; 
Gerhartz et al., 1996). Once STAT3 binds to the gp130 docking site, JAK then phosphorylates the recruited 
STAT3. Phosphorylated STAT3 forms a homodimer, which subsequently translocates into the nucleus, where 
it binds to gene enhancers to regulate target gene expression (Auernhammer and Melmed, 2000; Reich and Liu, 
2006; Chen et al., 2008). Although the LIF/JAK/STAT3 pathway has been well documented to maintain 
pluripotency of mouse ES cells in the presence of serum, the mechanisms by which activated STAT3 functions 
in this regard are poorly understood. A more recent study identified 718 STAT3-bound genomic sites that were 
co-occupied by pluripotency transcription markers (Oct4, Sox2 and Nanog) by using chromatin 
immunoprecipitation sequencing (ChIP-seq) (Chen et al., 2008). In addition, it was demonstrated that knocking 
down STAT3-target genes induces activation of endodermal and mesodermal genes, supporting the conclusion 
that STAT3 prevents mESC differentiation by suppressing lineage-specific genes (Bourillot et al., 2009). In 
mES cells, LIF can substitute MEF feeder layers in maintaining pluripotency in the presence of animal serum. 
However, in serum-free cultures, LIF is insufficient to block neural differentiation and maintain pluripotency. 
Interestingly, the LIF receptor and gp130 are also expressed in hESCs; however, LIF is unable to maintain the 
pluripotent state of hESCs, suggesting that mES and hES cells require distinct signalling mechanisms to 
regulate their pluripotency (Dahéron et al., 2004). 
 
Bone Morphogenetic Protein (BMP) is a member of the TGF-β superfamily (Sebald et al., 2004). BMP 
ligands bind to BMP receptors (BMPRs), the activated receptors phosphorylate BMP-responsive SMAD1/5/8 
(Small Mother Against Decapentaplegic) molecules, which subsequently form a complex with SMAD4 and 
translocate into nucleus to regulate target gene expression. In particular, SMAD complex activates inhibitors of 
differentiation (Id) genes, which block neural differentiation by antagonizing neurogenic transcription factors 
as well as inhibiting ERK (extracellular signal–regulated kinase) proteins (Ying et al., 2003b). In mES cells 
BMP was shown to be able to replace serum (Ying et al., 2003b), therefore, exogenous LIF in combination 
with BMP4 proteins can maintain the pluripotency of mouse ES cells in the absence of MEFs and serum. On 
the contrary, BMP was shown to promote human ES cells differentiation to trophoblasts, while inhibiting BMP 
signalling with the BMP antagonist, Noggin, sustained the undifferentiated state of human ES cells (Xu et al., 
2002, 2005). In line with these findings, dorsomorphin and DMH1, BMP inhibitors, were shown to promote 
long-term self-renewal and pluripotency of human ES cells, presumably by inhibiting BMP induced 
extraembryonic lineage differentiation (Yu et al., 2008; Hao et al., 2010, 2011; Gonzalez et al., 2011). 
 
The TGF-β/activin/nodal pathway consists of molecules belonging to the TGF-β superfamily, which are 
able to sustain human ES self-renewal and pluripotency (James et al., 2005; Vallier et al., 2005; Xiao et al., 
2006). The molecular mechanisms of this pathway implicate the activation of SMAD2/3, which induces (in 
combination with SMAD4) the expression of the pluripotent transcription factor Nanog (Xu et al., 2008). In 
contrast to its important role in maintaining hESC pluripotency, the TGF-β/Activin/Nodal signalling is not 
essential for pluripotency of mESCs. Although this pathway was shown to be active in undifferentiated mESCs 
as assessed by phosphorylation of SMAD2/3, inhibition of SMAD2/3 phosphorylation by the inhibitor 
SB431542 had no effect on the undifferentiated state of mESCs (James et al., 2005). However, the TGF-
β/Activin/Nodal signalling may play a role in mESC proliferation. Indeed, a recent study showed that 
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inhibition of TGF-β/Activin/Nodal signalling by SMAD7 or SB431542 dramatically decreased mESC 
proliferation without effect on their pluripotency (Ogawa et al., 2007). 
 
Finally, another crucial pathway for ESC pluripotency maintenance is FGF/MEK signalling. Although the 
role of exogenous FGFs (Fibroblast Growth Factors) in human ES cell has been known since a long time, the 
molecular mechanisms by which they function remain unclear. FGFs signal by binding to FGF receptors 
(FGFRs) activates multiple signalling cascades, including Mitogen-Activated Protein Kinases (MAPKs), the 
Janus kinase/signal transducer and activator of transcription (JAK/STAT), phosphatidylinositol 3-kinase 
(PI3K) and phosphoinositide phospholipase C (PLCg) pathway (Dailey et al., 2005). However, several studies 
have highlighted the FGFs contribution to the maintenance of human ES cells mainly through the FGF/MEK 
pathway (Kang et al., 2005; Li et al., 2007). FGF signalling in mESCs has also been extensively investigated. 
Mouse ESCs genetically deficient in FGF4 and extracellular-signal regulated kinase 2 (ERK2) differentiate 
inefficiently. These results can be reproduced using inhibitors of FGF receptor and ERK, suggesting that the 
blockage of the FGF/MEK signalling pathway may promote mESC pluripotency (Burdon et al., 1999; Kunath 
et al., 2007; Stavridis et al., 2007). Although inhibition of the FGF/MEK pathway can attenuate ES cell 
differentiation, it is insufficient to support mES cells self-renewal. Combination of the MEK inhibitor 
PD0325901 with the Glycogen synthase kinase-3 (GSK-3) inhibitor CHIR99021 (known as 2i) can efficiently 
sustain the pluripotency of mouse ES cells in the absence of exogenous cytokines (Ying et al., 2008; Smith and 
Ying, 2015). Several groups demonstrated that improvement of mouse ES cell pluripotency by inhibition of 
GSK-3 occurred via Wnt/β-catenin signalling, whereas many others argued that GSK3 was likely to exert β-
catenin independent effects in ES cells (Aubert et al., 2002; Kielman et al., 2002; Sato et al., 2004; Ogawa et 
al., 2006; Pereira et al., 2006; Takao et al., 2007; Ying et al., 2008; Wray et al., 2010). 
 
Overall these indications reveal that even if both human and mouse ESCs are derived from blastocyst-stage 
embryos, maintenance of their pluripotency requires different biological signals. In general, mouse ESCs 
maintain their pluripotency by activating LIF/STAT3 and BMP signalling, while human ESCs require TGF-
β/Activin/Nodal and FGF/MEK pathways. Interestingly, several pathways, such as BMP and FGF/MEK, have 
completely opposite effects on maintaining the pluripotency in these two different models. Indeed, activation 
of BMP signalling and inhibition of the FGF/MEK pathway promote mouse ES self-renewal, whereas 
inhibition of BMP signalling and activation of FGF/MEK pathway sustain human ESC pluripotency. These 
distinct signalling effects on pluripotency may reflect intrinsic differences between mouse and human ESCs. 
More recent studies have established that conventional human ES cells do not represent the “ground or naïve 
state” of stemness, but rather a more developmentally mature “primed state” resembling mouse epiblast stem 
cells (mEpiSCs) found in the post-implantation, pre-gastrulation stage of embryos (Tesar et al., 2007; Silva et 
al., 2008, 2009; Bao et al., 2009; Nichols and Smith, 2009; Hanna et al., 2010). Indeed, conventional hESCs 
exhibit numerous similarities to the mouse EpiSCs (E5.5-E7.5) over mouse ESCs (E3.5) (see Table 1.3).  
 
Pluripotency and self-renewal efficiency is governed by a gene regulatory network centred around three 
main transcription factors: Oct4, Sox2 and Nanog (Chambers and Tomlinson, 2009). In 1998, Austin Smith's 
group clarified the importance of Oct4 in the maintenance of a pluripotent state (Nichols et al., 1998). Oct4 is 
expressed in pluripotent cells and is specifically required for cells that become allocated to the interior of the 
blastocyst to acquire a pluripotent identity. The expression level of Oct4 is a critical determinant of the 
phenotype of ES cells and derivatives. In line with the in vivo phenotype, deletion of Oct4 results in 
differentiation of cells to a trophectodermal type. Sox2 is a member of the Sry-related HMG box family of 
transcription factors that interact with DNA through binding to the minor groove. Sox2 shares many of the 
same DNA targets as Oct4, with many of the characterized target sites being composites of the non-
palindromic Oct/Sox recognition sequences (Masui et al., 2007; Chambers and Tomlinson, 2009). Nanog is a 
homeobox-containing transcription factor whose DNA-binding domain adopts a typical three helix structure 
that binds to the TAAT DNA sequence (Chambers et al., 2003, 2007). In vivo analysis of Nanog-null embryos 
indicates that the latter is essential for the specification of the pluripotent epiblast similarly to the requirement 
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for Oct4. Genomic studies revealed that Oct4, Sox2, and Nanog frequently bind to the same regulatory regions 
in undifferentiated mouse and human ESCs, and that these binding sites are often in close proximity to one 
another (Loh et al., 2006; Tesar et al., 2007; Mathur et al., 2008; Sharov et al., 2008). These results indicate 
that Oct4, Sox2, and Nanog may physically interact with each other and, in some cases, coordinately regulate 
target genes. Additionally, it was reported that these combinatorial Oct4/Sox2/Nanog binding sites were more 
conserved between mouse and human ES cells compare to those individual (Boyer et al., 2005; Loh et al., 
2006; Wang et al., 2006; Masui et al., 2007; Göke et al., 2011). 
 
 
                       
 
Figure 1.5. Signalling pathways required to support pluripotency in mouse/human ES cells (from Han et al., 2013). 
Exogenous growth factors signal through distinct signalling pathways to regulate transcription factors for ES cell 
pluripotency.  
 
 
 
 
 
 
 
 
 
  
 
Table 1.3. Comparison of the properties of mouse ES cells (mESCs), mouse epiblast stem cells (mEpiSCs), human 
ES cells (hESCs) and human iPS cells (hiPSCs) (adapted from Han et al., 2013). 
Property mESCs mEpiSCs hESCs hiPSCs 
Morphology domed flattened flattened flattened 
Clonogenicity high (single cells) 
low 
(clumps) 
low 
(clumps) 
low 
(clumps) 
Response to 
LIF/Stat3 self-renewal none none none 
Response to 
Activin/bFGF differentiation self-renewal self-renewal self-renewal 
Response to 
BMP self-renewal differentiation differentiation differentiation 
XX status XaXa XaXi XaXi XaXi 
Teratoma yes yes yes yes 
Chimaera yes no ND ND 
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1.3.2 From ESCs to neurons: neural differentiation protocols 
Based upon their proliferative and pluripotential properties, ESCs are an attractive alternative to fetal or adult-
derived central nervous system tissue and a useful tool for studying the mechanisms underlying embryonic 
development and cell differentiation. In recent years, several research groups have developed experimental 
protocols to induce ES cells to differentiate into numerous cell types. Among these protocols, particular 
attention has been paid to neural induction protocols, which allow the conversion of ESCs into neural cells.  
 
Based on the work in non-mammalian species, particularly Xenopus laevis and chick, a “default model” 
hypothesis emerged for neural specification, proposing that in the absence of cell-cell signalling, ectodermal 
cells will adopt a neural fate (Muñoz-Sanjuán and Brivanlou, 2002). Several studies support this hypothesis for 
ESC neural differentiation, as well. For example, a study showed that when mouse ES cells are grown in the 
absence of feeder layers or exogenous factors (i.e. at very low cell density under which factors become 
limiting), roughly 70% of the cells die within 24 hours; of the remaining cells, the majority (82%) expresses 
the NESTIN (a specific marker of neural progenitors, Lendahl et al., 1990), indicating that the default fate of 
dissociated mouse ES cells is neural (Tropepe et al., 2001). However, many other studies in adherent 
monoculture support an alternative hypothesis as they sustain that, although the elimination of inductive 
signals for alternative fates is sufficient for ES cells to develop into neural precursors, this process is not a 
simple default pathway but requires autocrine FGF (Li et al., 2001; Ying and Smith, 2003; Ying et al., 2003a). 
This second hypothesis is also supported by observations in Xenopus and chick, where positive factors are 
required for neural conversion, and once the neural transition is achieved, signals are necessary to promote the 
survival and proliferation of these committed cells (Stern, 2005). In conclusion, the mechanism of 
neuroectoderm formation from pluripotent founder cells is controversial, and remains heavily debated. 
 
In general, two types of experimental approaches for differentiating towards an in vitro neural fate have 
been proposed: Embryoid Bodies (EBs) and monolayer cultures (see Table 1.4 adapted from Cai and Grabel, 
2007 that documents the properties of six principal protocols using ESCs to derivate Neural Stem Cells, 
NSCs). 
 
(i) EBs (3D cultures): mimicking neural specification during embryogenesis. Initial studies demonstrated that 
the generation of neural cell types from mouse ESCs were based upon the formation of intermediates called 
embryoid bodies. This method tried to recapitulate the multistep process of neural development that occurs in 
the embryo. When mouse ESCs are removed from their feeder layer, and placed in suspension culture in the 
absence of the growth factor LIF, they form aggregates, which within 2-4 days consist of an outer layer of 
hypoblast-like cells (extraembryonic visceral endoderm) surrounding an epiblast-like core (primitive ectoderm) 
(Rathjen et al., 2002; Cai and Grabel, 2007). The EB core continues to express the ESC marker Oct4 and 
begins to express the primitive ectoderm marker FGF5. Between day 6 and 8, the core undergoes cavitation 
and forms an inner epithelial layer. Cells within this layer can be committed to definitive ectoderm, 
characterized by Sox2 and Otx2 expression. Subsequently, a re-organization into a columnar epithelium, 
resembling the neural tube (rosette), is accompanied by the expression of neurectoderm-specific markers such 
as Sox1 and Six3 (Rathjen et al., 2002; Maye et al., 2004). Moreover, it has been shown that retinoic acid 
causes a massive increase of the yield of neural lineage cells generated by EBs protocol (Guan et al., 2001; 
Gottlieb, 2002).  
 
(ii) Monolayer culture: depriving ESCs of both cell-cell interactions and signals by culture in serum-free 
medium. Given the evidence for a default pathway of neural induction, in which the absence of signals 
promotes this lineage specification, several approaches for promoting neural differentiation of ESCs include a 
selection step of culture in a serum-free, nutrient-poor neurobasal medium. Indeed, direct differentiation of 
ESCs to neural stem cells (NSCs) can be obtained under serum-free conditions in monolayer culture at 
moderate cell densities. This differentiation protocol was established by the Smith’s laboratory using the 
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mouse ESC line 46C. Cells are plated at around 1×104 cells/cm2 on gelatin-coated dishes in the absence of LIF 
in serum-free defined medium (N2B27 medium). Within 5 days, up to 75% of the cells become NESTIN+ and 
form neural rosettes in which cells elongate and align radially, in a manner reminiscent of the neural tube 
formation, as well as ectoderm and neuroectoderm differentiation in ESC embryoid bodies (Ying and Smith, 
2003; Ying et al., 2003a). Thus, regardless of the adopted protocol, the signature of neural progenitors in 
culture is the appearance of the neural rosettes. 
 
 
 
 
 
 
 
Table 1.4. Comparison of protocols using ESCs to derive NSC (adapted from Cai and Grabel, 2007). ESCs, embryonic 
stem cells; NSCs, neural stem cells; RA, retinoic acid; CM, conditioned medium; NA, not applicable; GFAP, glial fibrillary 
acidic protein; FBS, fetal bovine serum; NCAM, nerve cell adhesion molecule; En1-2, Engrailed 1-2; MAP2, microtubule 
associated protein 2; GABA, γ-aminobutyric acid. 
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1.3.3 Neural rosette formation as in vitro model for neurogenesis 
The development of the nervous system can be divided roughly into three processes; neural induction, 
neurulation, and regional specification. Cues taken from the embryo during each of these processes have been 
useful in establishing methods for in vitro neural differentiation. In particular, in vitro rosette formation of 
NSCs is widely and reliably used as a model system for reproducing in vivo neurogenesis. NSCs derived from 
ESCs, generated from both adherent and embryoid body-intermediate approaches, typically arrange themselves 
radially on a flat surface, eventually forming a central lumen. This radial, floral-like arrangement is known as 
“rosette”. Neural rosettes have a structural and functional similarity to the embryonic neural tube (Figure 1.6). 
Morphological similarities are not the only common feature, indeed both rosettes and neural tube display 
localized zones of proliferation and can be patterned by signalling molecules and growth factors, suggesting 
that their formation and differentiation are governed by similar mechanisms (Wilson and Stice, 2006; Elkabetz 
et al., 2008). Interestingly, multicellular rosettes have been recently appreciated as important cellular 
intermediates during the formation of other organ systems, such as kidney tubule elongation, pancreatic 
branching morphogenesis, Drosophila eye development and many others (Harding	 et	 al.,	 2014). Several 
studies have also revealed that the cytoskeletal rearrangements responsible for rosette formation appear to be 
conserved. By contrast, the extracellular cues that trigger these rearrangements in vivo are more diverse and 
less well understood (Harding et al., 2014). 
 
Rosettes were identified at the end of the 18th century by James Homer Wright (Lee et al., 2002) and Simon 
Flexner (Flexner, 1891). These structures were described as a precise histologic architectural pattern detected 
within specific nervous system tumours (neuroblastoma, medulloblastoma, retinoblastoma, ependymoma and 
pineocytoma). In the early 1960s, while Pierce and co-workers were investigating the potency of embryonal 
carcinoma cells that back then were used as analogue for early embryo cells in differentiation studies, some 
rosettes-reminiscent structures were identified in embryo bodies and were correlated for the first time to neural 
development (Pierce and Verney, 1961). In 1975, Martin and Evans (Martin and Evans, 1975) obtained similar 
results from in vitro experiments performed on embryonal carcinoma cells and in 1991 Kawata and colleagues 
described the in vitro neural rosette formation obtained from a clonal human teratocarcinoma cell line (Kawata 
et al., 1991). In 1995, for the first time post-mitotic neurons from ES cells were generated (Bain et al., 1995); 
soon after, in 1996, Ronald McKay and co-workers optimised the protocol to achieve up to 95% NESTIN+ 
cells in the proliferation phase and >60% MAP2+ cells after differentiation. According to this protocol, by 5-7 
days a large proportion of the surviving NESTIN+ cells developed a small elongated shape and were organised 
in a rosette-like structure (Okabe et al., 1996). In 2001, Zhang and co-workers reported the appearance of 
neural rosettes in one of the first neural differentiation experiment with human embryonic stem cells (Zhang et 
al., 2001). More recently, many researchers explored whether the neural rosettes and the radial arrangement of 
neural progenitors in the neural tube are produced by similar mechanisms.  
 
Below is a summary of these studies and their findings: 
 
(i) During neural differentiation mouse ESC-derived NSCs exhibit distinct bipolar cell shape, a 
morphological characteristic of radial glia. Meanwhile, radial glia were recognized as the NSCs of the 
embryonic neural tube, which give rise to the variety of neurons and glia of the nervous system (Noctor et al., 
2001). Mouse ESC-derived NSCs were found to express proteins characteristic of radial glia, i.e. RC2 and 
brain lipid binding protein (BLBP) (Figure 1.6) (Bibel et al., 2004). Human ESC-derived rosette NSCs also 
demonstrate radial glia-like properties (Elkabetz et al., 2008). Moreover, global gene expression and 
immunocytochemistry analysis performed using human ESC-derived rosette NSCs illustrate the capacity of 
these cells to give rise to multiple neuronal subtypes of both the central and peripheral nervous systems 
(Elkabetz et al., 2008). Glial subtypes, such as astrocytes (Elkabetz and Studer, 2008) and oligodendrocytes 
(Hatch et al., 2009), have also been produced from rosette NSCs. 
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(ii) The neural tube consists of a radially arranged neuroepithelium surrounding a central lumen. The side 
of the epithelial cell layer facing the lumen (ventricles) is considered apical, while the side facing the outer pial 
surface is considered basal. Apicobasal polarity is quickly established following the closure of the neural tube, 
partially due to the asymmetric distribution of proteins involved in adherent and tight junction formation 
(Miyata, 2007). The neural progenitors that compose the rosettes show the same antigenic characteristics of the 
cells in the neural tube in formation (Abranches et al., 2009). In fact, to recognize neural progenitors during 
differentiation, immunocytochemical analysis can be performed using the antibody directed against 
cytoplasmic protein NESTIN. This is an intermediate filament protein (IF) type VI (Michalczyk and Ziman, 
2005; Guérette et al., 2007), expressed mainly in the cytoskeleton of neural progenitor cells, where it is 
involved in the radial growth of axon. Additionally, the tight junction zona occludens 1 (ZO1) protein is 
expressed exclusively at the apical surface of cells surrounding the lumen of the neural tube. Its localization 
coincides with expression of the neuroepithelial adhesion marker N-cadherin (N-Cad) (Figure 1.6) (Marthiens 
and ffrench-Constant, 2009). This asymmetric expression pattern is also observed in ESC-derived neural 
rosettes, where ZO1 protein is observed initially at tight junctions between cultured ESCs. However, at the 
onset of neural differentiation, this protein is rapidly redistributed and restricted to the centre of emerging 
rosettes (Elkabetz et al., 2008). Similarly to in vivo immunohistochemical analysis of the neural tube, ZO1 and 
N-Cad also show significant overlap in domains of expression in vitro at the luminal side of the neural rosette, 
where a correct cell polarity was established (Figure 1.6). Three major protein complexes are involved in 
establishing cell polarity: crumbs (CRB), partition-defective (PAR) and discs large (DLG) complexes 
(Margolis and Borg, 2005). CRB complex is required to determine the apical membrane and consists of the 
transmembrane CRB protein and the cytoplasmic proteins PALS1 and PATJ (Margolis and Borg, 2005). PAR 
complex, on the other hand, contributes in defining the apico-lateral membrane and includes PAR3, PAR6, 
aPKC and CDC42 proteins (Margolis and Borg, 2005). Finally, the DLG complex delineates the base-lateral 
plasma membrane and consists of Scribble, Lgl (Lethal giant larvae) and Dlg (Discs large) proteins (Margolis 
and Borg, 2005). These three complexes have an antagonistic action and are the crucial players in the 
regulation of the cell polarity, following a spatial-temporal order and interacting with different proteins of 
cellular adhesion and cytoskeleton (Margolis and Borg, 2005). 
 
(iii) A work from Lorenz Studer’s research group focused on the identity of hESC-derived neural rosettes, 
finding that by default such neural rosettes adopt polarized neuroepithelial structures of anterior CNS fate 
including expression of Foxg1b (BF1) (Elkabetz et al., 2008). Indeed, in the absence of extrinsic patterning 
cues neural rosettes acquire markers of anterior neural ectoderm. However, neural rosette stage cells can also 
undergo anteroposterior specification and, after specific treatments with sonic hedgehog (SHH) and retinoic 
acid (RA) or SHH and FGF8, spinal motoneurons and midbrain precursors were obtained, respectively 
(Elkabetz et al., 2008). Moreover, the differentiation of neural rosette progeny in the presence of ventral and 
dorsal patterning cues such as SHH or Wnt3A led to the induction of markers compatible with ventral 
forebrain fate and the emergence of GABA+ neurons and cells expressing dorsal markers such as Msx1. The 
anterior CNS bias of neural rosettes is reminiscent of the default model postulated in classical studies of 
Xenopus CNS development in which it was found that anterior CNS fates are established first and are followed 
by caudal transformation in response to secreted signals (Elkabetz et al., 2008).  
 
(iv) A well-known feature of neural tube cells is the interkinetic nuclear migration (INM), a precise 
movement of cell nuclei according to their cell cycle stage (Sauer and Walker, 1959). Nuclei within rosettes 
undergo similar migration. Nuclei undergoing DNA synthesis were located at the basal side of the cells 
(visualized by BrdU incorporation), whereas mitotic nuclei were always confined to the luminal side, as shown 
by phosphohistone H3 (PH3) antibody staining. PH3 and BrdU stainings never overlapped, indicating a highly 
controlled spatial confinement, which normally occurs in the proliferating neural tube (Abranches et al., 2009).  
 
(v) In the embryonic neuroepithelium, the Notch pathway controls the rate at which proliferating neural 
progenitors commit to differentiation. When Notch activity is inhibited, precocious neuronal differentiation is 
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usually observed. Similarly, depletion of Notch signalling in rosette cultures causes rosette progenitors to 
embark on neuronal differentiation (Abranches et al., 2009). 
 
Overall, the results indicate that neuroepithelial rosette cultures recapitulate several aspects of embryonic 
neural tube development and early mammalian neurulation events. They, therefore, represent a good 
experimental system to study early stages of neural development in vitro encompassing neural induction and 
neurulation.  
 
 
 
 
Figure 1.6. ESC-derived neural rosettes in vitro bear striking resemblance to the neural tube (from Germain et al., 
2010). Apicobasal polarity is similar between rosettes and the neural tube, with tight junctions (indicated by ZO1 
expression, blue) at the apical surface forming a lumen. Radially arranged progenitors in the rosette, as well as the neural 
tube, express RC2 and BLBP (green). 
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Aim 
 
 
This thesis work aims at investigating whether the polyQ domain in HTT is functionally relevant during in 
vitro neurogenesis. A mES cell-based platform for complementation assays with HTT fragments mutated or 
deleted in the CAG tract has been set up to this purpose. Subsequently, these cell lines were subjected to neural 
differentiation and analysed by a rosette assay. This in vitro assay measures the ability of ES cell-derived 
neural progenitors to form neural rosettes, which are radial arrangements of columnar cells expressing many of 
the proteins found during neural tube formation in vivo. The work is divided in two phases. 
 
(1) In the first phase, we generated mES cell lines bearing N-terminal HTT carrying different polyQ tract 
variants. In particular, the selected CAG repeat variations were the deletion, substitutions, and length 
modification (both in the normal and pathological range). The newly generated cell lines were then tested in a  
neural induction protocol to evaluate their rosette formation capacity, by measuring (i) the percentage of neural 
progenitor cells organized in rosettes, (ii) rosette size and (iii) rosette lumen size. 
 
(2) Secondly, we worked on the rosette assay procedure in order to develop a novel automated system to 
perform unbiased and quantitative assessment of the rosette phenotypes in vitro. 
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Cell lines. We used mouse ES cell lines expressing the wild-type Hdh gene (Hdh+/+) or being homozygous 
knockout for the gene (Hdh-/-), in which both alleles of the Hdh gene were inactivated by deletion of exons 4 
and 5 (Duyao et al., 1995). All complemented cells were derived by the transfection of pCAG in Hdh-/- cells. 
Both Hdh+/+ and Hdh-/- were analysed for karyotypic abnormalities (Q-banding) and they showed several 
common chromosomal alterations at the cell population level (the most frequent were duplications of 
chromosomes 1, 8, 11 and 14) (Rebuzzini et al., 2008). 
 
Mouse ES cell culture. ES cells were maintained in Glasgow minimal essential medium supplemented with 
10% heat-inactivated fetal bovine serum (vol/vol, EuroClone, REF ECS0186L), 0.1mM β-mercaptoethanol 
(Gibco, REF 31350-010), 100µM non-essential amino acids (Gibco, REF 11140-035, 1mM sodium pyruvate 
(Gibco, REF 11360-039), 2mM l-glutamine, 100U/mL penicillin, 100µg/mL streptomycin (EuroClone, REF 
ECB3001D) and 1,000U/mL murine leukemia inhibitor factor (LIF, ESGRO) (Millipore, REF ESG1107) in 
gelatinized tissue culture flasks. Cells were passaged every 2 days after dissociation with 0.05% trypsin-EDTA 
(vol/vol) (Gibco, REF 15400-054). 
 
Plasmids. The constructs, encoding for the N-terminal portions of mouse (Mm) or human (Hs) HTT, were 
designed according to previously published HTT multiple sequence alignment (Tartari et al., 2008) and cloned 
in pCAG plasmids. Below are reported the newly generated plasmids:  
§ pCAG Mm 0Q 
§ pCAG Mm 2Q 
§ pCAG Mm 4Q 
§ pCAG Mm 7Q 
§ pCAG Mm Q3PQ3 
§ pCAG Mm Q3Q(CAA)Q3 
pCAG Hs 15Q and pCAG Hs 128Q were previously generated in the laboratory. 
 
Bacteria transformation. Under a sterile environment, 1µL of re-suspended plasmid (40ng/µL) has been 
added to a single 50µL vial containing DH5α bacteria. After 30 minute of ice incubation, tubes are transferred 
in a heating block at 42°C for 30 seconds and then for 2 minutes in ice again (step of thermal shock required to 
make membrane permeable to DNA). Then, 250µL of S.O.C. solution (w/v: 2% tryptone, 0.5% yeast extract, 
10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4, 20mM glucose, Invitrogen) are added and cells are 
incubated for 1 hour at 37°C. At the end of incubation, bacteria are plated on warmed LB-agar plates (Luria-
Bertani Broth w/v: 1% tryptone, 0.5% yeast extract, 10mM NaCl, 1.5% agar) containing ampicillin. Thanks to 
the ampicillin resistance gene present in the transformed plasmids, only bacteria that have incorporated it will 
grow in presence of ampicillin. Plates are incubated over-night at 37°C, to make transformed bacteria able to 
grow and to form single colonies. 
 
DNA maxi-preparation. QIAGEN Plasmid Maxi kit has been used according to the manufacturer’s 
instructions. Single bacterial colonies were picked from a selective plate and inoculated in 4 mL of Luria-
Bertani Broth (LB) (w/v: 1% tryptone, 0.5% yeast extract, 10mM NaCl) medium containing the ampicillin. 
Bacteria solutions were incubated over-night at 37°C with vigorous shaking. 300µL of this starter culture were 
inoculated in 300mL of LB medium containing the appropriate selective antibiotic. Bacteria were grown at 
37°C for 12-16 hours with vigorous shaking. Bacterial cells have been harvested by centrifugation at 4500xg 
for 30 min at 4°C. Pellet was re-suspended in 10mL of Buffer P1. 10 mL of Buffer P2 was added for cell lysis. 
The tube was mixed thoroughly by vigorously inverting it 4-6 times, and incubated at room temperature (15-
25°C) for 5 min. 10mL of chilled Buffer P3 were added, mixed immediately and thoroughly by vigorously 
inverting 4-6 times, and incubated on ice for 20 minutes. Tubes were centrifuged at 10,000xg for 30 minutes at 
4°C. During centrifugation, QIAGEN-tip 500 was equilibrated by applying 10mL Buffer QBT (750mM NaCl; 
50mM MOPS, pH 7.0; 15% isopropanol (v/v); 0.15% Triton Xa-100 (v/v)), and allowed the column to empty 
by gravity flow. The supernatant was applied to the equilibrated QIAGEN-tip and allowed to enter the resin by 
gravity flow. QIAGEN-tip has been washed 2 × 30mL with Buffer QC (1.0M NaCl; 50mM MOPS, pH 7.0; 
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15% isopropanol (v/v)). DNA was eluted with 15mL Buffer QF (1.25M NaCl; 50mM Tris-HCl, pH 8.5; 15% 
isopropanol (v/v)). DNA was then precipitated by adding 10.5mL of room-temperature isopropanol. Mixed and 
centrifuged immediately at 10,000xg for 30 min at 4°C. The supernatant was removed and DNA pellet washed 
with 5ml of room-temperature 70% ethanol, and centrifuged at 10,000xg for 10 minutes. The supernatant was 
removed and the pellet air-dried for 5-10 minutes. DNA was re-dissolved in 150-200µL of H2O. At the end of 
this maxi-preparation, extracted DNA was used to transfect mES cells after DNA quality the control and 
quantification. 
 
Plasmid DNA quality control and quantification. The plasmid DNA obtained after maxi-preparation was 
quantified with Nanodrop 1000 (Thermo Fisher Scientific) spectrophotometer. The same analysis also allows 
to evaluate the purity of the plasmid DNA solution. To verify that the constructs, encoding for N-terminal 
fragments of HTT, were properly inserted in the pCAG plasmids with their correct length, an enzyme digestion 
was performed using the restriction enzymes NotI and XhoI. The pCAG plasmid has two restriction sites 
specifically recognized by this enzyme: one site is immediately upstream of the N548 fragment while the 
second one is downstream of it. If the N-terminal fragment has been inserted properly, the enzymatic digestion 
will produce two fragments of about 6.4Kb and 1.7Kb. We then performed DNA electrophoretic on 1% 
agarose gel in order to separate the fragments by their size. The gel was visualized through a transilluminator 
(Molecular Imager Gel DocTM Xr Imaging System, Bio-rad) and images were analysed with Quantity One 
(Bio-rad) software. 
 
DNA transfections. Hdh-/- ES cells were plated at a density of 2 x 104 cells per cm2. After 24 h, Lipofectamine 
2000 (Invitrogen) was used to transfect the cells with different expression vectors (10µg). Cells were selected 
for effective transfection with puromycin (2µg/ml) 24 h after lipofection, and for 10 days. Western blot and 
immunocytochemistry were performed to determine the expression of the transgene.  
 
Mouse ES cell monolayer differentiation. ES cells were dissociated and plated onto 0.1% gelatin-coated 
tissue culture dishes at a density of 2.5-4 x 104 cells per cm2 in N2B27 medium. Medium was renewed every 2 
days. N2B27 medium was a 1:1 mixture of DMEM/F12 and Neurobasal medium containing 1:200 N2 
supplement (Gibco, REF 17502-048), 1:100 B27 supplement (Gibco, REF 17504-044) and 0.1mM β-
mercaptoethanol (Gibco, REF 31350-010). Under this monoculture condition, in the absence of LIF, mES cells 
lose pluripotent status and commit to a neural fate over 5-6 days (Ying and Smith, 2003; Ying et al., 2003a). 
Figure 3.1 recapitulates specifications of the protocol applied.  
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Figure 3.1. Schematic representation of the neural differentiation protocol. 
 
Immunocytochemistry. Cells were fixed in 4% paraformaldehyde for 15 min at room temperature (20-23°C). 
They were subsequently permeabilized and blocked in blocking buffer containing PBS with 0.5% Triton X-100 
(vol/vol) and with 5% fetal bovine serum (vol/vol) for 1 h at room temperature. Primary antibodies were 
diluted in blocking buffer and incubated overnight at 4 °C. After three washes in PBS, appropriate secondary 
antibodies, conjugated to Alexa fluorophores 488 or 568 (Molecular Probes, Invitrogen) and were diluted 
1:500 in blocking solution, and incubated for 1 h at room temperature. Cells were incubated for 10 min with 
Hoechst 33258 (5µg/mL, Molecular Probes, Invitrogen) for nuclear counterstaining. Images were acquired 
with a Leica DMI 6000B microscope (equipped with LAS-AF imaging software) and processed with the 
software ImageJ (US National Institutes of Health). 
 
Antibodies. The following antibodies (Abs) and dilutions were used for immunocytochemistry and western 
blot:  
Monoclonal Ab for HTT (Millipore, Mab2166; immunofluorescence, 1:800; western blot, 1:1000) 
Monoclonal Ab for NESTIN (Millipore, Mab353; immunofluorescence, 1:200) 
Polyclonal Ab for ZO1 (Life Technologies, REF 402300; immunofluorescence, 1:200) 
Monoclonal Ab for OCT4 (SantaCruz, SC-5279; immunofluorescence, 1:100) 
Polyclonal Ab for NANOG (Abcam, ab21624; immunofluorescence, 1:100) 
Polyclonal Ab for PALS1 (Life Technologies, sc-33831; immunofluorescence 1:200)	
Polyclonal Ab for αPKC (Life Technologies, sc-216; immunofluorescence 1:200)	
Polyclonal Ab for PAR3 (Millipore, cod. 07-330; immunofluorescence 1:200)	
 
Protein lysates and western blot. Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 
0.1% SDS, 1% nonidet P40, 0.5% sodium deoxycholate, wt/vol) with 1 mM PMSF and protease inhibitor 
(Thermo Scientific, REF 1861281). Lysates were cleared by centrifugation at 12,000g and 4 °C for 30 min. 
The resulting supernatant was collected. Protein concentration was determined with the Pierce-BCA Protein 
assay kit (Thermo Scientific REF 23225) and 30µg were loaded on a 7.5% SDS-PAGE gel. Separated proteins 
were transferred to a nitrocellulose membrane, blocked with 5% non-fat dry milk (wt/vol, Bio-rad, REF 170-
6404) in Tris-buffered saline (TBS) with 0.1% Tween-20 (vol/vol), and incubated with primary antibody at 
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room temperature for 3 h. After washing, filters were incubated for 1 h at room temperature with a secondary 
antibody (peroxidase conjugate, Bio-rad, 1:3000) and then washed three times with TBS and 0.1% Tween-20. 
The Clarity Western ECL Substrate (Bio-rad, REF 170-5061) was used to visualize immunoreactive bands by 
chemiluminescence detection with ChemiDoc MP Imaging System (Bio-rad). 
 
Rosette quantification. Rosettes were quantified in cell cultures on day 7 of neural differentiation after 
staining for NESTIN and ZO1. Twelve images of random fields for each cell line were acquired. Each 
experiment was independently repeated at least three times. Rosette quantification consists of measuring three 
parameters: (i) percentage of NESTIN+ cells inside the rosette, area of each (ii) rosette and (iii) lumen. Figure 
3.1 shows the pipeline developed using the ImageJ software. For the measurement of the percentage of 
NESTIN+ cells inside rosettes, we firstly calculated the total area occupied by NESTIN+ cells. Second, the 
shape of each rosette was outlined and the area occupied by the NESTIN staining was considered as the area 
occupied by NESTIN+ cells inside the rosettes. The remaining NESTIN+ signal was selected as the area 
occupied by NESTIN+ cells outside the rosettes. For rosette and lumen size, the contour of each rosette (as 
highlighted by the marker NESTIN) and that of each rosette’s lumen (as highlighted by marker ZO1) was 
manually outlined and two lists of regions of interest (ROIs) were measured to calculate rosette and lumen 
mean area, respectively. 
 
 
 
 
Figure 3.2. Step-by-step rosette quantification (manual method). 
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Apoptosis Assay. Cells were seeded in triplicate in two 96-well plates, at 16 x 103 cells per well. After 24-h 
incubation at 37 °C, cells received 100µl of freshly prepared GMEM+LIF without serum. 48 h after plating, 
100µl of CellTiter Reagent (Promega, REF G7570) was added to all wells. After 10 min of incubation at room 
temperature, luminescence was measured with a Veritas-MicroplateLuminometer (Turner Biosystems) to 
detect cell viability. Caspase-Glo 3/7 Reagent (100µl, Promega, REF G8091) was added to all parallel wells. 
After 30 min of incubation at room temperature, luminescence was recorded with a Veritas-
MicroplateLuminometer (Turner Biosystems) to detect Caspase-3/7 activity. Each experiment was 
independently repeated at least three times. Results are presented as the ratio of caspase-3/7 luminescence and 
cell viability luminescence recorded for each cell line. 
 
Statistical analyses. The difference between all cell lines was tested using generalized linear mixed models 
assuming a binomial error distribution and a logit link-function (for the variable: % NESTIN+ cells inside 
rosettes) or a Gaussian error distribution and an identity link-function (for the variables: rosette and lumen 
size). In modelling the percentage NESTIN+ cells we considered experiment and well as random effect factors. 
In modelling rosette and lumen size we considered experiment, well and field as random effect factors. Post 
hoc comparisons between cell lines were performed by applying Bonferroni procedure. The difference between 
cell lines in the Caspase-3 activity was tested in linear mixed models assuming a Gaussian error distribution 
and an identity link-function. The random effect of the experiment was included in the model. Post hoc 
comparisons between cell lines were performed by applying the Bonferroni procedure. 
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4.1 HTT rosette formation potential is confined to its N-terminal portion 
Previous studies have shown that HTT is important for rosette formation. In fact, HTT depletion in Hdh-/- cells 
leads to a reduction in rosette formation and size while complementation with the N-terminal 548aa portion of 
the protein is able to restore proper rosette formation and size in the same cells (Lo Sardo et al., 2012).  
In the first part of this thesis work I further tested the robustness of the data already published in Lo Sardo et 
al., 2012. To this aim I have prepared replicate experiments in which I evaluated the rosette formation 
potential, by measuring (i) the percentage of NESTIN+ cells organized in rosettes, (ii) the rosette size and (iii) 
the rosette lumen size. The results obtained confirmed that Hdh-/- neural progenitors cells have a drastically 
reduced capacity to generate proper rosettes and lumens (see column 2 and 3 of Table 4.1, 4.2, 4.3, 4.4 for the 
number of experimental replicates). We then confirmed that the expression of the N-terminal portion of HTT 
alone in Hdh-/- cells (7Q cells) completely rescues rosette formation by promoting the organization of high size 
mature rosettes with large and well-defined lumens (see column 5 of Table 4.1, 4.2 and column 4 of Table 4.3 
for the number of experimental replicates). 
4.2 Generation of cell lines stably expressing mutated versions of the CAG tract 
In order to determine whether the HTT polyQ domain is implicated in rosette formation, we performed a series 
of variations in this area and tested their effect in a Hdh-/- cell-based complementation assay. N-terminal HTT 
portions carrying selected polyQ variations were cloned into a pCAG plasmid, a mammalian expression vector 
that contains a strong CAG promoter ensuring stable and continued expression of the transgenes in mES cells 
(Figure 4.1a,b). Specifically, we generated the following N-terminal HTT variants: 
(i) a mouse N-terminal HTT construct deleted of the polyQ region; 
(ii) a mouse N-terminal HTT construct carrying either 2 or 4 glutamines. We decided to test the 2Q-stretch 
because this is the first polyQ tract appearing in deuterostome evolution, in echinoderms. On the other 
hand, we opted for the 4Q-stretch in order to mimic the second step of polyQ evolution i.e. the 4Qs found 
in lower vertebrates (birds, reptiles, fishes and amphibians); 
(iii) a mouse N-terminal HTT construct in which synonymous (CAG replaced with CAA, encoding for a 
glutamine) and non-synonymous (CAG replaced with CCG, encoding for a proline) substitutions were 
introduced in the 4th position of the CAG tract. We decided to use a proline interruption since several 
proteins harbouring a polyQ tract also carry prolines. Moreover, since proline has different physical-
chemical properties with respect to glutamine, and provides rigidity to the polypeptide chain of the 
protein, we predicted this mutation could significantly alter the structure of the polyQ tract. On the 
contrary, the replacement of a CAG codon with a CAA (synonymous substitution) should not affect the 
biological function of the tract, as the amino acidic sequence remains unaltered. 
 
Schematic diagrams of HTT constructs bearing different polyQ mutations are reported in Figure 4.2a. All 
pCAG vectors were transfected in Hdh-/- mES cells and after 10 days of puromycin selection we pooled 
selected cells. Transgene expression was assessed by western blot and immunocytochemistry analysis using 
MAB2166 antibody that recognizes the N-terminal portion of HTT. Western blot analysis detected expression 
of the transgenes at the expected size in the transfected Hdh-/- cell lines, whereas the control cell lines 
(untransfected Hdh+/+ and Hdh-/- cells) showed no transgene expression as expected (Figure 4.2b,c). 
Immunocytochemistry analysis corroborated transgene expression and revealed that HTT fragments are 
confined to the cell cytoplasm (Figure 4.2d). We have also evaluated the pluripotency state of these newly 
generated cell lines and found that OCT4 and NANOG expression were similar between untransfected and 
transgene expressing cells (Figure 4.3).  
Results 
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Figure 4.1. Generation of pCAG plasmids with the HTT sequences encoding for different HTT N-terminal 
fragments. (a) Schematic representation of the experimental strategy used to generate pCAG plasmids. (b) Gel 
electrophoresis of the pCAG plasmid products (pCAG N548 0Q, -2Q, -4Q, -7Q, Q3Q(CAA)Q3, and –Q3PQ3) digested by 
NotI and XhoI enzymes. For each gel, lane 1: pCAG plasmid product (Uncut); lane 2: pCAG plasmid digested product 
(Cut); lane 3: 1Kb DNA Ladder (M). 
 
 
 
Figure 4.2. Hdh-/- cells overexpressing HTT N-terminal fragments with mutations in the polyQ tract. (a) Schematic 
representation of expression vectors carrying murine and human HTT N-termini (Mm, Mus musculus; Hs, Homo sapiens) 
with different polyQ lengths/modifications. (b,c,d) MAB-2166 (anti-HTT) Western blot (b,c) and immunostaining (d) in 
self-renewal conditions of Hdh-/- cell lines that overexpress murine or human HTT N-termini with different polyQ 
lengths/substitutions. The scale bars correspond to 50µm. Insets are shown at 2X magnification. 
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4.3 PolyQ stretch deletion causes defects in rosette formation 
To investigate the possible role of the polyQ tract in neurulation, we tested rosette formation potential in 
polyQ-depleted cells (0Q cells) by using Hdh+/+ and 7Q cells as positive controls while Hdh-/- cells were used 
as negative controls. Differentiated cells were fixed at day 7 and stained with antibodies against NESTIN and 
ZO1 markers (Figure 4.4a,b; see Figure 3.1 for a schematic representation of neural differentiation protocol). 
NESTIN is a type VI intermediate filament protein that marks the intermediated filaments of the cytoskeleton 
of the neural cells during the radial growth of their axons (Lendahl et al., 1990), while ZO1 is a protein present 
within the occluding junctions which identifies the rosette lumen (Marthiens and ffrench-Constant, 2009). 
 
In order to test the activity of polyQ-deleted N-terminal HTT upon expression in Hdh-/- cells we exposed the 
cells to neural induction and monitored the appearance of rosettes over time. In Figure 4.4c,d,e 0Q cells 
exhibit an impairment of rosette formation, as judged by the percentage of NESTIN+ cells inside rosettes as 
well as smaller rosette and lumen areas (Figure 4.4c,d,e). In particular, we found that in six independent 
experiments, the percentage of NESTIN+ cells inside the rosettes was significantly reduced in 0Q cells 
(47.5±6.7%) compared to Hdh+/+ and 7Q control cell lines (89.2±1.3% and 87.8±2.8%, respectively). 
Moreover, the mean rosette area, calculated on 271 images from a total of 2938 rosettes, was approximately 
50% smaller in 0Q cells compared to Hdh+/+ and 7Q cells. We also evaluated the lumen size of the rosettes, as 
it mirrors the enhanced or reduced numbers of neural progenitors that compose the rosettes. By measuring a 
total of 1241 lumens we report a significant reduction of the mean lumen size in 0Q cells, where the average 
area was about 3 times smaller than the one measured in Hdh+/+ and 7Q cultures. See Table 4.1 for the number 
of experimental replicates. 
Our in vitro results suggest that the polyQ tract may have played a role in the appearance and/or evolution 
of a nervous system, as demonstrated by the lower percentage of neural progenitors organized in rosettes as 
well as by the smaller size of rosettes and lumens in 0Q cultures. 
 
 
Figure 4.4. Effects of HTT polyQ tract deletion in an ES cell-derived neural rosette assay mimicking early 
neurulation. (a) Diagram of the different HTT N-terminal portions assessed, in which the polyQ tract modifications (with 
or without polyQ) are highlighted (b) Representative images of rosette/lumen phenotype in Hdh+/+, Hdh-/-, 0Q and 7Q ES 
cells stained for NESTIN and ZO1 at day 7 of neural induction. (c,d,e) Percentage of NESTIN+ cells inside rosettes, rosette 
and lumen mean area in Hdh+/+, Hdh-/-, 0Q, and 7Q ES cells exposed to neural induction. Data are expressed as mean ± 
SEM. See Table 4.1 for the number of biological replicates. All pairwise statistical comparisons were run by applying 
generalized linear mixed models with a post hoc Bonferroni correction (*: P<0.05; ***: P<0.001). The scale bars 
correspond to 50µm. Insets are shown at 2X magnification. 
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4.4 PolyQ stretch increases rosette formation in a length-dependent manner 
Bioinformatics studies established that the length of the polyQ tract increases throughout the evolution of 
deuterostomes, in concomitance with the emergence of progressively more complex nervous systems (Tartari 
et al., 2008). On this basis, we speculated that the effect of HTT polyQ tract on rosette formation could be Q-
dependent, and that more Q in HTT could lead to a progressively more important rescue in the rosette 
phenotype in Hdh-/- cells (described in 4.3). To test this hypothesis, cell lines carrying a mouse HTT N-
terminal transgene bearing 0Q, 2Q, 4Q or 7Q were differentiated in an unique subset of replicate experiments 
(Table 4.2). Our data showed that the length of Q stretch linearly covaries with rosette formation potential 
(Figure 4.5). In fact, an increase in CAG length leads to a higher percentage of NESTIN+ cells organized in 
rosettes, as well as to larger lumen and to an increase in rosette area (P value < 0.001 in all three parameters 
measured; See Table 4.2 for the number of experimental replicates).  
These results suggest that the number of Q in HTT acts as a fine modulator of the pro-neurulation function 
of the protein.  
 
 
 
 
Figure 4.5. Effects of HTT polyQ tract length in an ES cell-derived neural rosette assay mimicking early 
neurulation. (a) Diagram of different HTT N-terminal portions assessed, in which the polyQ tract modifications (polyQ 
tract length) are highlighted (b) Representative images of rosette/lumen phenotype in 0Q, 2Q, 4Q and 7Q ES cells stained 
for NESTIN and ZO1 at day 7 of neural induction. (c,d,e) Regression lines and confidence intervals between Q length and 
rosette/lumen phenotypic variables in neuralized 0Q, 2Q, 4Q and 7Q ES cells. See Table 4.2 for the number of biological 
replicates. All pairwise statistical comparisons were run by applying generalized linear mixed models with a post hoc 
Bonferroni correction (***: P<0.001). The scale bars correspond to 50µm. Insets are shown at 2X magnification. 
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4.5 Interruption of polyQ tract purity reduces in vitro neurulation 
We next investigated whether an interruption in the CAG tract tarnishes rosette formation potential. 
Specifically, we performed differentiation experiments with cells bearing a CCG substitution that causes a 
replacement from a glutamine to proline (Q3PQ3 cells) or a CAA synonymous substitution that leads to no 
amino acid replacement (Q3Q(CAA)Q3 cells) in the 4th position of the polyQ tract. Our complementation 
assays showed that the presence of a proline in the mouse polyQ tract in the 4th aa position causes a reduced 
percentage of neural progenitors organized in rosettes with respect to control Hdh+/+ and 7Q cultures (Figure 
4.6c, columns 1, 3, and 4). We also found that a proline interruption of the CAG tract leads to the formation of 
smaller rosettes and lumens compared to Hdh+/+ and 7Q cells (Figure 4.6d,e, columns 1, 3, and 4). By 
contrast, a CAA synonymous substitution in 4th position of the mouse CAG stretch did not affect the rosette 
phenotype in all three parameters assessed (Figure 4.6c,d,e, column 5). See Table 4.3 for the number of 
experimental replicates. 
Overall, these findings indicate that preservation of an unaltered polyQ tract is important for rosette 
formation. 
 
 
 
 
 
Figure 4.6. Effects of HTT polyQ tract interruption in an ES cell-derived neural rosette assay mimicking early 
neurulation. (a) Diagram of different HTT N-terminal portions assessed, in which the polyQ tract modifications (polyQ 
tract interruptions) are highlighted (b) Representative images of rosette/lumen phenotype in Hdh+/+, Hdh-/-, 7Q, Q3PQ3, 
and Q3Q(CAA)Q3 ES cells stained for NESTIN and ZO1 at day 7 of neural induction. (c,d,e) Percentage of NESTIN+ 
cells inside rosettes, rosette and lumen mean area in Hdh+/+, Hdh-/-, 7Q, Q3PQ3, and Q3Q(CAA)Q3 ES cells exposed to 
neural induction. Data are expressed as mean ± SEM. See Table 4.3 for the number of biological replicates. All pairwise 
statistical comparisons were run by applying generalized linear mixed models with a post hoc Bonferroni correction (*: 
P<0.05; ***: P<0.001). The scale bars correspond to 50µm. Insets are shown at 2X magnification. 
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4.6 Pathological HTT polyQ tract impairs neurulation 
To assess the activity of a pathologically expanded polyQ tract in the same assay, we exposed mES cells 
bearing a human N-terminal HTT construct with a pathological 128Q stretch (128Q cells) to neural induction 
(Figure 4.7a,b). We found that the percentage of NESTIN+ cells inside the rosettes was drastically reduced in 
128Q cells (29.6±8%), and to the same extent as observed in Hdh-/- cultures (24.0±9%), (Figure 4.7c, columns 
2 and 4) but was preserved in mES cells bearing human HTT N-terminal fragment with normal 15Q stretch 
(15Q cells, 80.6±4%), as observed in control Hdh+/+ cells (74.7±6%), (Figure 4.7c, columns 1 and 3). Rosette 
and lumen sizes were also significantly reduced by approximately 2-fold in 128Q cells (as occurred in Hdh-/- 
cells) compared to 15Q cells (Figure 4.7d,e, columns 2, 3 and 4). Data are expressed as mean ± SEM (see 
Table 4.4 for the number of experimental replicates). On the whole, these findings showed that a pathological 
CAG expansion (128Q) affects HTT pro-neurulation function, suggesting that, during evolution, a CAG 
expansion beyond a certain threshold may have been detrimental. 
 
 
 
 
Figure 4.7. Effects of human HTT pathological polyQ tract in an ES cell-derived neural rosette assay mimicking 
early neurulation. (a) Diagram of different HTT N-terminal portions assessed, in which the polyQ tract modifications 
(polyQ tract with normal and pathological length) are highlighted (b) Representative images of rosette/lumen phenotype in 
Hdh+/+, Hdh-/-, 15Q, and 128Q ES cells stained for NESTIN and ZO1 at day 7 of neural induction. (c,d,e) Percentage of 
NESTIN+ cells inside rosettes, rosette and lumen mean area in Hdh+/+, Hdh-/-, 15Q, and 128Q ES cells exposed to neural 
induction. Data are expressed as mean ± SEM. See Table 4.4 for the number of biological replicates. All pairwise 
statistical comparisons were run by applying generalized linear mixed models with a post hoc Bonferroni correction (***: 
P<0.001). The scale bars correspond to 50µm. Insets are shown at 2X magnification. 
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4.7 PolyQ domain is not involved in the antiapoptotic function of HTT 
Since HTT protein and its N-terminal portion were previously associated with an antiapoptotic function (Lo 
Sardo et al., 2012), we evaluated whether Hdh-/- cells complemented with N-terminal  HTT fragment with 0Q 
were protected from apoptosis under serum starvation. We first verified the previous data by confirming that 
Caspase-3 activity is increased in HTT-depleted (Hdh-/-) cells compared to Hdh+/+ (P value < 0.001; Figure 4.8 
columns 1 and 2), while the exogenous expression of HTT N-terminus with its normal Q in Hdh-/- cells (7Q 
cells) prevents cell death (Figure 4.8 column 4). Notably, level of Caspase-3 activity observed in 0Q cells was 
similar to that occurred in Hdh+/+ and 7Q cells (Figure 4.8 column 1, 3 and 4). Therefore, the polyQ tract in 
HTT N-terminus is not required for the antiapoptotic function of the protein. Overall, our findings demonstrate 
that while the pro-neurulation function of HTT is linked to a persistent CAG tract, HTT antiapoptotic activity 
lays within other domains of the HTT N-terminus. 
 
 
 
Figure 4.8. Effect of the polyQ tract deletion on the HTT anti-apoptotic function. Caspase-3 activity in proliferating 
Hdh+/+, Hdh-/-, 0Q and 7Q ES cells exposed to serum deprivation condition. Data are the mean ± SEM, n=10 independent 
experiments. Statistical pairwise comparisons were performed using a generalized linear mixed model with post hoc 
Bonferroni correction (**: P<0.01, ***: P<0.001). 
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Table 4.1. Subset of experiments to evaluate the effect of HTT polyQ tract deletion in rosette assay. Top: independent 
experiments analysed to measure the percentage of NESTIN+ cells inside rosette; middle: independent experiments 
analysed to measure the rosette size; bottom: independent experiments analysed to measure the lumen size. 
 
 
 
Table 4.2. Subset of experiments to evaluate the effect of HTT polyQ tract length in rosette assay. Top: independent 
experiments analysed to measure the percentage of NESTIN+ cells inside rosette; middle: independent experiments 
analysed to measure the rosette size; bottom: independent experiments analysed to measure the lumen size. 
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EXP  Hdh +/+  Hdh -/- 0Q 7Q 
1 90,72 56,97 33,74 84,16 
2 83,50 72,17 75,80 77,16 
3 92,41 24,02 35,00 88,94 
4 90,07 55,94 35,00 92,16 
5 90,74 19,37 51,76 96,97 
6 87,92 61,99 53,87 87,54 
Mean 89,23 48,41 47,53 87,82 
SD 3,16 21,53 16,50 6,79 
SEM 1,29 8,79 6,74 2,77 
R
os
et
te
 a
re
a 
(µ
m
2 )
 
EXP  Hdh +/+  Hdh -/- 0Q 7Q 
1 18343,2 6818,0 8594,2 16203,4 
2 14945,0 12202,6 6375,1 12537,2 
3 27287,3 6173,4 11055,8 18181,0 
4 18233,6 8937,8 12940,3 - 
5 21792,2 5839,2 8899,8 22283,7 
6 20951,9 12937,9 7768,3 19595,3 
Mean 20258,87 8818,17 9272,22 17760,11 
SD 4200,93 3108,38 2361,76 3664,35 
SEM 1715,02 1268,99 964,18 1638,75 
Lu
m
en
 a
re
a 
(µ
m
2 )
 EXP  Hdh +/+  Hdh -/- 0Q 7Q 
1 691,2 88,7 160,5 620,6 
2 1138,0 148,9 428,7 679,9 
3 458,3 151,0 244,4 1126,5 
4 903,1 97,3 - - 
Mean 797,63 121,45 277,84 808,99 
SD 290,64 33,10 137,20 276,52 
SEM 145,32 16,55 79,21 159,65 
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EXP 0Q 2Q 4Q 7Q 
1 33,74 50,01 62,61 84,16 
2 - 51,24 74,08 - 
3 51,16 75,27 89,08 88,94 
4 53,87 82,89 82,59 87,54 
Mean 46,26 64,85 77,09 86,88 
SD 10,93 16,73 11,44 2,45 
SEM 6,31 8,36 5,72 1,42 
R
os
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 a
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a 
(µ
m
2 )
 (g
)  
EXP 0Q 2Q 4Q 7Q 
1 8594,2 9137,5 11866,0 16203,4 
2 - 12770,5 12175,6 - 
3 6375,1 - - 12537,2 
4 11055,8 7149,6 10760,5 18181,0 
5 8899,8 - - 22283,7 
6 7768,3 13147,6 13694,6 19595,3 
Mean 8538,62 10551,31 12124,19 17760,11 
SD 1713,48 2900,36 1210,38 3664,34 
SEM 766,29 1450,18 605,19 1638,74 
Lu
m
en
 a
re
a 
(µ
m
2 )
 (h
)  EXP 0Q 2Q 4Q 7Q 
1 160,5 173,8 443,5 620,6 
2 - 174,7 515,2 - 
3 428,7 195,9 586,8 679,9 
4 244,4 521,3 694,0 1126,5 
Mean 277,84 266,43 559,86 808,99 
SD 137,20 170,22 106,88 276,52 
SEM 79,21 85,11 53,44 159,65 
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Table 4.3. Subset of experiments to evaluate the effect of the purity interruption of the HTT polyQ tract in rosette 
assay. Top: independent experiments analysed to measure the percentage of NESTIN+ cells inside rosette; middle: 
independent experiments analysed to measure the rosette size; bottom: independent experiments analysed to measure the 
lumen size. 
 
Table 4.4. Subset of experiments to evaluate the effect of the pathological HTT polyQ tract in rosette assay. Top: 
independent experiments analysed to measure the percentage of NESTIN+ cells inside rosette; middle: independent 
experiments analysed to measure the rosette size; bottom: independent experiments analysed to measure the lumen size. 
%
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EXP  Hdh +/+  Hdh -/- 7Q Q3PQ3 Q3Q(CAA)Q3 
1 63,99 31,44 82,65 39,35 - 
2 58,90 45,90 68,89 76,63 - 
3 64,04 10,14 73,26 - - 
4 66,41 11,31 82,63 56,03 - 
5 81,59 30,22 62,15 48,30 77,17 
6 65,11 35,04 - 42,08 - 
7 81,31 26,41 52,92 - 70,66 
8 93,61 5,45 81,60 70,41 73,01 
9 80,52 27,73 71,04 63,49 74,66 
10 71,50 16,77 85,23 50,75 78,58 
Mean 72,70 24,04 73,37 55,88 74,82 
SD 11,01 12,76 10,90 13,35 3,17 
SEM 3,48 4,03 3,63 4,72 1,42 
R
os
et
te
 a
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a 
(µ
m
2 )
 EXP  Hdh +/+  Hdh -/- 7Q Q3PQ3 Q3Q(CAA)Q3 
1 16614,0 5388,2 29834,0 10121,7 - 
2 15866,6 6529,8 - 8174,7 22407,0 
3 35614,8 7384,9 18162,5 16377,0 20691,4 
4 19409,0 8091,2 16565,40 13508,4 21041,4 
5 22765,4 6995,2 24093,7 6820,5 18477,5 
Mean 22053,97 6877,88 22163,91 11000,45 20654,31 
SD 8051,02 1010,37 6052,81 3918,75 1629,05 
SEM 3600,52 451,85 3026,40 1752,52 814,53 
Lu
m
en
 a
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a 
(µ
m
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EXP  Hdh +/+  Hdh -/- 7Q Q3PQ3 Q3Q(CAA)Q3 
1 719,2 145,7 1144,6 145,9 - 
2 651,1 234,9 - 282,2 988,5 
3 718,3 109,1 549,4 322,1 788,2 
4 1176,8 250,5 598,2 223,9 658,0 
5 692,1 103,6 866,2 192,9 543,1 
Mean 791,48 168,79 789,60 233,42 744,47 
SD 217,14 69,62 274,62 70,09 191,05 
SEM 97,11 31,14 137,31 31,34 95,53 
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EXP  Hdh +/+  Hdh -/- 15Q 128Q 
1 88,37 15,28 68,29 11,33 
2 64,01 4,28 84,84 39,93 
3 63,99 31,44 87,24 21,53 
4 82,23 45,17 82,04 45,44 
Mean 74,65 24,04 80,60 29,56 
SD 12,55 17,97 8,48 15,88 
SEM 6,27 8,98 4,24 7,94 
R
os
et
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 a
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a 
(µ
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 EXP  Hdh +/+  Hdh -/- 15Q 128Q 
1 34195,0 22478,9 30928,3 18500,2 
2 23884,4 13832,2 28933,5 7106,7 
3 27803,8 8186,0 15214,8 8047,8 
Mean 28627,75 14832,38 25025,56 11218,22 
SD 5204,45 7198,75 8554,68 6323,90 
SEM 3004,79 4156,20 4939,04 3651,11 
Lu
m
en
 a
re
a 
(µ
m
2 )
 EXP  Hdh +/+  Hdh -/- 15Q 128Q 
1 722,8 124,9 548,3 110,1 
2 637,3 96,6 571,9 138,5 
3 760,9 215,9 1061,8 216,6 
4 708,5 163,9 307,2 154,9 
Mean 707,34 150,33 622,31 155,00 
SD 51,70 51,69 316,46 45,04 
SEM 25,85 25,85 158,23 22,52 
Results 
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4.8 Automatization of rosette assay for high-content analysis 
Identification and analysis of rosette formation are tedious and subjective procedures due to the acquisition of 
random fields and the manual quantification of rosettes and lumens. Thus, phenotype quantification could be 
directly influenced by the operator visual bias. For this reason we designed a novel automated method based on 
an image analysis algorithm for unbiased and quantitative assessment of rosette phenotypes. The relevance of 
this effort is to make our rosette assay a high-content imaging-based approach for classifying a larger and more 
diverse panel of phenotypes during in vitro neurulation. To this aim we focused, in the first step, on adopting 
the neural differentiation setup for high-content analyses and, subsequently, on developing an image analysis 
pipeline for rosette quantification. 
4.8.1 Optimization of neural differentiation protocol procedures 
Initially, we worked on the scaling down of the multi-well plate format, a parameter essential for high-content 
analysis. Moreover, the multi-well plates adopted have to be compatible with the automated equipment and 
imaging analysis. In the manual rosettes assay we used normal polystyrene 12-well plates coated with 0.1% 
gelatin. Polystyrene plates are ideal for cell attachment and subsequent differentiation, but they exhibit reduced 
optical properties compared to glass bottoms or polymer coverslip (optical plastic) plates. To overcome this 
issue, we tested several multi-well plates and, on the basis of the capacity of the cells to adhere and uniformly 
disperse in the well, we selected optical plastic 24-well plates (IBIDI, cod. 250210). These plates, in addition to 
permit cell adhesion, possess high-quality plastic bottoms ideal for image acquisition and analysis. 
Additionally, in order to allow ES cells to differentiate toward monodispersed neural rosettes (this is a 
condition more suitable for the automatic quantification), we also tested different basement membrane matrices 
and cell density conditions. In particular, after testing different substrate conditions (without substrate, with 
gelatin 0.05%, 0.1%, 0.2% and with matrigel substrate) and cell density (from 1x104/cm2 to 1,5x105/cm2) we 
selected gelatin 0.1% and a cell density of 2.5-3.5x104 cells/cm2 as the optimal neural differentiation condition.  
For immunostaining of the neural rosettes in the automated assay, we used NESTIN (to identify neural 
progenitors) and ZO1 (to identify the tight junctions in the rosette lumen) markers, as in the manual method. 
However, when we tested new lumen markers to better identify the area of rosette apical site we revealed that 
among ZO1, PALS1, PAR3, and αPKC (four polarity markers targeting the tight junctions, described in 1.3.3) 
the antibodies against ZO1 and PALS1 were more suitable for our purposes due to their reduced aspecific 
binding (see Figure 4.9a) compared to the anti-PAR3 and -αPKC antibodies. Moreover, anti-PALS1 antibody 
gave a more intense and defined staining of the lumen compared to the antibody against ZO1 (see Figure 
4.9b). Therefore, we decided to use PALS1 as a new marker for the identification of lumens in both manual 
and automated rosettes assay. 
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Figure 4.9. Comparison of four different antibodies against ZO1, PALS1, aPKC and PAR3 polarity markers. (a) 
Immunocytochemistry analysis on the Hdh+/+ cell line at day 7 of neural differentiation carried out using antibodies against 
ZO1, Pals1, aPKC and PAR3 polarity markers (green) and against NESTIN (red). All fields were acquired with Leica DMI 
6000 microscope at magnification 10X. (b) Representative image stitching of immunocytochemistry analysis on the Hdh+/+ 
cell line at day 7 of neural differentiation carried out using antibodies against ZO1, Pals1 polarity markers and against 
NESTIN marker. The arrow indicates an example of intense and defined lumen staining. 
a 
b 
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4.8.2 Automatization of image acquisition and rosette quantification 
An automated image acquisition pipeline was applied by using the IN Cell Analyzer 1000. This instrument is 
an automated cellular and subcellular imaging system for fast, automated multi-wavelength imaging and 
analysis in fixed and live cells. The powerful, easy-to-use IN Cell Analyzer 1000 enhances the productivity of 
cell-based approaches for high-content cellular analysis, by combining system flexibility with superior image 
and data quality. In particular, we have set up an acquisition of 40 random fields for each well at 10X 
magnification, in contrast with 4 random fields acquired during the manual method by using Leica DMI 6000 
microscope.  
A specific protocol for automated quantification was set up with IN Cell Developer Toolbox software. 
Given that rosettes are complex structures defined by multiple components (NESTIN+ area that covers the 
scaffold of the rosette, ZO1+ area that corresponds to the central lumen, and Hoechst positive nuclei that 
represent the number of cells in the rosette) and present heterogeneous sizes and shapes, a multi-step protocol 
is required. Indeed, for the protocol to work, the putative rosette must meet a series of criteria, each of which is 
identified in a single step of the pipeline. For convenience, we can divide the protocol in nine steps able to 
identify several target sets: steps from 1 to 3 are relevant for the identification, by Hoechst staining, of the 
rosette cells’ nuclei; steps from 4 to step 7 permit to identify the lumens, using ZO1 as a marker; steps from 5 
to 9 lead to rosette identification, using NESTIN as a marker. Below we report the individual steps of the 
pipeline set up. 
Step 1: Identification of large Hoechst positive areas. In particular, here we proceeded with object 
segmentation followed by some image-processing algorithms, named post-processing steps, among which 
dilation (the effect of this operation is to gradually enlarge the boundaries of regions of the target set), targets 
filled (with which the software fills the holes inside the identified objects), and sieve (used to refine a 
segmented image by removing objects or artifacts belonging to a particular size range). On the whole, these 
post-processing operations allow to identify big clusters of nuclei that we will use in step 6 to separate the 
rosettes clumped together.  
Step 2: Identification of Hoechst positive cells. Here we applied object segmentation followed by erosion, a 
function that strongly contracts the region’s outer boundary of the target set in order to obtain the “seeds of the 
signal”. These signal seeds provide a mask that we will apply in the next step. 
Step 3: These are post-processing steps that include sieve, erosion, and clump-breaking that separates the 
clumps of objects using the mask generated in Step 2. After this, we will obtain the proper nuclei identification 
of the cells that forms the rosettes. 
Step 4: Identification of lumens. We perform an object segmentation step followed by sieve and dilation as 
post-processing steps. Moreover, SD-levels (standard deviation of pixel densities within the target) and Dens-
levels (mean signal level value of the pixels contained within the target) were registered to establish the proper 
values to use as acceptance criteria. Only the ZO1+ areas that satisfy the acceptance criteria values are 
recognized as lumens. 
Step 5: Identification of total NESTIN signal area. We performed the detection process named intensity 
segmentation followed by sieve as post-processing step in order to identify the whole NESTIN signal area. 
Step 6: Identification and split of the putative NESTIN+ rosettes. We performed intensity segmentation 
followed by sieve post-processing step and subsequently we applied clump-breaking function that separates the 
clumps of rosettes using the mask of large Hoechst positive areas identified in Step 1. We thus obtain the 
single putative NESTIN+ rosette. 
 
Since the final targets of interest (neural rosettes) are composed by multiple elements, we performed a 
series of target linking operations (Steps 7 to 9) in order to create a link between targets identified and to 
pinpoint real rosettes that satisfy all criteria described above.  
 
Step 7: Rosettes and lumen association. We performed an operation of one to one link between ZO1+ 
lumens identified in Step 4 and NESTIN+ rosettes identified in Step 6. By using 75% of overlap between 
ZO1+ lumens and NESTIN+ rosettes as criterion, we selected only one possible ZO1+ lumen for each single 
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rosette. After this step the number of all putative lumens identified in Step 4 decreases, ensuring a more precise 
identification of real lumens associated with rosettes.  
Step 8: Rosette and nuclei association. We performed a one to many link between nuclei identified in Step 
3 and NESTIN+ rosettes identified in Step 6. By using 80% of overlap between nuclei and NESTIN+ rosettes 
as criterion, we identified the nuclei that belong to each single rosette. 
Step 9: Identification of real rosettes with nuclei and lumens. By using a composed one to one link between 
previously-linked target sets in Step 7 and 8, we identify only the rosettes that present both a lumen and the 
nuclei. Those are the rosettes that we consider as real rosettes and on which we focused our attention for the 
analysis.  
 
Figure 4.10 recapitulates all steps, described above, and demonstrates the efficiency of the pipeline in 
recognizing neural rosettes and their associated parameters. Particularly, from this multi-step analysis we get a 
series of parameters related to the three targets identified (nuclei in Step 3; lumens and rosettes in Step 7 and 9, 
respectively) as well as parameters from several combinations of these three targets. Indeed, while the manual 
rosette assay quantified with ImageJ analysis software is able to provide only 3 parameters (percentage of 
NESTIN+ cells inside rosette, rosette size and lumen size) through the automated rosette assay we increase the 
number of parameters measured from 3 to 13. In particular, we have the possibility to measure: 
 
a. Neural induction (neural conversion, total NESTIN+ signal area over Dapi+ cells) 
b. Percentage of NESTIN+ cells inside rosettes 
c. Number of rosettes 
d. Rosette size (area) 
e. Rosette perimeter 
f. Rosette shape (ratio between rosette area and perimeter) 
g. Rosette cell density (number of Dapi+ cells inside a rosette over its area) 
h. Lumen formation (total ZO1+ signal area over total NESTIN+ signal area) 
i. Lumen size (area) 
j. Lumen perimeter 
k. Lumen fiber length (total length within a single fibrous shape) 
l. Lumen max chord (maximum distance across the inside of a target) 
m. Lumen form factor (estimate of circularity) 
 
Additionally, the automated rosette assay allows to increase 10-20 times the amount of data collected with 
respect to manual counting. Indeed, the automated system allows to measure the parameters from about 1000-
2000 rosettes for each experiment and for each cell line, while the manual quantification allows to collect data 
from approximately 100 rosettes for each cell line. 
On the whole, this unbiased approach permits to further improve rosette acquisition/quantification and to 
strongly increase the rosette measurements dataset, leading to development of an automated assay for high-
content analysis of in vitro neurulation. 
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4.8.3 Evaluation of rosette phenotype by automated method 
In order to test the new automated method and validate the previous manually quantified rosette phenotypes, 
we performed 4 independent neural differentiation experiments with Hdh+/+ and Hdh-/- cells. We confirmed the 
defects in rosette formation in Hdh-/- cells with respect to Hdh+/+ by assessing the percentage of NESTIN+ cells 
inside rosettes (P<0.001; Figure 4.11b). Moreover, the mean rosette area was approximately 40% smaller in 
Hdh-/- cells compared to Hdh+/+ cells, a result that mirrors the previously acquired manual data (P<0.001; 
Figure 4.11d). We also evaluated the lumen of the rosettes, and we confirmed a significant reduction of the 
mean lumen size that was approximately 3 times smaller in Hdh-/- cells compared to Hdh+/+ cells (P<0.001; 
Figure 4.11i). Overall these findings corroborated the ones obtained with manual quantification. 
 
As described before, the automated rosette quantification allows to measure a series of additional 
parameters. In particular, we observed that neural induction, number of rosettes, rosette perimeter, lumen 
formation, lumen perimeter, lumen fiber length and lumen max chord were significantly reduced in Hdh-/- 
cultures compared to Hdh+/+ cultures (all P values were <0.001; Figure 4.11a,c,e,h,j,k,l, respectively). Instead, 
there is a significant increase in the lumen form factor parameter in Hdh-/- cells with respect to Hdh+/+ cells 
(P<0.01; Figure 4.11m). No significant difference was detected in the rosette shape and rosette cell density 
parameters (Figure 4.11f,g). Besides validating the rosette phenotype in Hdh-/- cells, the automated procedure 
can extend the spectrum of parameters that we can assess in the rosette analysis, therefore increasing 
exponentially the power of our analyses. 
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Figure 4.10. Automated rosette quantification method. (a) Sequence of the steps developed for the automated rosette 
quantification by IN Cell Developer Toolbox software. (b) Example of automated rosette identification by IN Cell 
Developer Toolbox software. Yellow line indicates the counter of the rosette; green line indicates the counter of the lumen. 
 
 
 
 
 
 
Nestin, Zo1, Hoechst Hoechst Identification of cell clusters by Hoechst signal 
Nestin (Millipore, MAB353, 1:200) 
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Figure 4.11. Quantification of rosette phenotype by automated method. Quantification of rosette and lumen parameters 
in Hdh+/+ and Hdh-/- cells by using the automated procedure: (a) neural induction, (b) percentage of NESTIN+ cells inside 
the rosettes, (c) number of rosettes, (d) rosette size, (e) rosette perimeter, (f) rosette shape, (g) rosette cell density, (h) 
lumen formation, (i) lumen size, (j) lumen perimeter, (k) lumen fiber length, (l) lumen max chord, and (m) lumen form 
factor. Data are the mean ± SEM, n=4 independent experiments (T-test; **: P<0.01; ***: P<0.001; ns: not significant). 
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Previous studies showed that HTT is important for rosette formation as cultures of Hdh-/- mES cells are 
severely deficient in rosettes formation and only show small sized rosettes (Lo Sardo et al., 2012). Our 
complementation assays showed that constitutive expression of exogenous normal full length mouse HTT or 
its N-terminal 548aa portion, in Hdh-/- cells restores proper rosette formation and size (Lo Sardo et al., 2012). 
While these findings have associated the ability to form neural rosettes to the HTT N-terminal portion, here we 
show, for the first time, a direct link between the HTT polyQ tract and the capacity of the cells to form proper 
rosettes. Indeed, the deletion of the sole Q domain from HTT N-terminus leads to a reduction in the neural 
rosette formation potential, as demonstrated by the quantification of the percentage of neural progenitors 
organized in rosettes as well as by the size of the rosettes and their lumens (Figure 4.4). Although we provide 
evidences of a role of the HTT polyQ tract during in vitro neurulation, an open question still remains on the 
functional role of the wild-type polyQ tract in vivo during the early phases of neural development. Studies 
carried out by S. Zeitlin’s group have shown that the HdhΔQ-ΔQ knock-in mice are born with normal Mendelian 
frequency with no gross phenotypic differences with respect to control littermates. However, they exhibit 
subtle behavioural phenotypes in motor and cognitive tests (Clabough and Zeitlin, 2006). This may be an 
indication of other unknown molecular defects or of the presence of in vivo compensatory effect that still need 
to be investigated. Therefore, the rosette assay captures only a small snapshot of what happens in vivo and may 
not give the whole picture of the complex biological systems surrounding nervous system development. 
However, it can zoom in and analyse with a high degree of accuracy the binary connection between HTT 
function and its evolutionary role in nervous system development.  
 
We have also observed that modulation of polyQ length regulates neural progenitor organization in a dose-
dependent manner, since its elongation from 0 to 7Q improves the ability of ES cell-derived neural progenitors 
to form rosettes. The finding that rosette formation potential linearly covaries with CAG length (Figure 4.5) 
suggests that the number of glutamines in the polyQ domain may act as a ‘fine-tuning knob’ of the HTT-
dependent rosette formation mechanisms. These data are in line with the hypothesis of Fondon and colleagues, 
that states that the trinucleotide repeats could play a relevant and potentially beneficial role in evolution. These 
repeats, by virtue of their special mutational and functional properties, modify genes with which they are 
associated, thus generating the genetic variation that underlies adaptive evolution (King et al., 1997; Fondon et 
al., 2008). More specifically, the mutational expansion of certain triplet repeats is implicated not just in 
hereditary neurodegenerative disease but also in normal brain development and behavioural traits (Fondon et 
al., 2008). Our observation of a polyQ length-dependent neurulation activity is also in line with previous 
indications derived from complementation experiments with HTT homologs bearing CAG tracts that increase 
in length during human lineage evolution. These findings indicated that cells expressing heterologous HTT 
fragments from progressively more recently evolved species show an increased rosette formation potential (Lo 
Sardo et al., 2012). However, on the basis of data from Lo Sardo et al., 2012 we cannot directly link the ability 
to modulate neural rosette formation with polyQ length, as it is not the only element to differ in the tested 
heterologous HTT fragments. On the contrary, in this thesis, we exclusively used mouse HTT fragments 
bearing 0, 2, 4 and 7Q thus focusing on the effect of the sole polyQ tract. This allows us to assign a direct 
relationship between polyQ length and rosette formation potential.  
 
As the polyQ tract is conserved throughout evolution (Tartari et al., 2008), we tested whether an amino 
acid interruption in the polyQ sequence is compatible with HTT neurogenic potential. We observed that a CAA 
synonymous substitution does not affect the rosette formation phenotype (Figure 4.6). In contrast, the P 
interruption in the same position generates ES cell derived neural progenitors cultures with fewer and smaller 
rosette and lumen area (Figure 4.6). These findings underline the need to preserve the polyQ tract unaltered, as 
the interruption of its purity by a proline results in a reduction of HTT pro-neurulation potential. 
Our experiments also show that a 128Q domain (bearing a pathological polyQ length) in HTT N-terminus 
determines a reduced rosette formation potential, with a significant decrease in the ability of neural progenitors 
to self-organize in rosettes together with a reduction of lumen and rosette areas (Figure 4.7). Collectively, the 
results described here suggest that there may be a neurodevelopmental component in Huntington Disease 
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(HD). This is in agreement with data from Molero and colleagues (Molero et al., 2016) in which the expression 
of mutant HTT exclusively until postnatal day 21 in HD mice displayed similar profiles of impairments to mice 
expressing mutant HTT throughout life, advancing the hypothesis that neurodevelopmental aberrations may 
play important roles in HD pathogenesis and progression (Molero et al., 2016). Accordingly, smaller 
intracranial volume in individuals with prodromal HD provides a further in vivo evidence for abnormal 
neurodevelopment in HD (Nopoulos et al., 2011b).  
Finally, we show that HTT molecules carrying either 0 or 7Q upon expression in Hdh-/- cells are all equally 
capable of conferring protection from apoptosis after serum starvation (Figure 4.8). These results revealed that, 
while the pro-neurulation function of HTT is linked to the CAG repeat tract, the antiapoptotic activity of HTT 
lies within other domains of its N-terminus. 
 
In conclusion, in this study we show, for the first time, that the stretch of Q in HTT is biologically active 
during early neurogenesis since its deletion, its pathological expansion or its interruption directly impairs HTT 
pro-neurulation activity, while its elongation in the normal range (from 0 to 7Q) progressively increases the 
neurogenic power of this protein.  
 
The main readout of our experiments is the quantitative and qualitative evaluation of rosette formation, 
however the current methodology is a time consuming procedure subject to an examiner’s bias. By adopting an 
automated image acquisition procedure with the IN Cell Analyzer 1000 we developed a cell-based high-
content analysis platform to better assess a different spectrum of parameters surrounding rosette formation 
(Figure 4.10 and 4.11). Moreover, the same platform could be also exploited to investigate novel HTT 
phenotypic targets.  
 
In this thesis we worked with HTT null ES cells overexpressing several N-terminal portions of the protein. 
In order to further assess the functional relevance of these domains in a more physiological condition, we are 
currently generating knock-in mES cell line bearing a Recombinase Mediated Cassette Exchange (RMCE) by 
CRISPR-Cas9 technology. This RMCE cassette spans the promoter, the first exon and part of the first intron of 
the HTT gene allowing efficient insertions of any mutated HTT exon 1 in the endogenous locus. Therefore, this 
cassette has two main advantages compared to the overexpressing fragments used up till now: the first is that it 
allows expression of the full-length HTT containing the variants of interest; the second, is that it integrates in 
the endogenous locus and therefore is exposed to the natural genomic environment of HTT allowing a better 
reproduction of the HTT aura and its physiological expression. In a future series of analyses we also plan to 
investigate other potential contributions of the polyQ tract in diverse HTT activities as well as the role of the 
N17 and PRD domains in neural and non-neural HTT functions.  
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